TY  - JOUR
AU  - Mačvanin, Mirjana
AU  - Gluvić, Zoran
AU  - Zafirović, Sonja
AU  - Gao, Xin
AU  - Essack, Magbubah
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10613
AB  - An imbalance between pro-oxidative and antioxidative cellular mechanisms is oxidative stress (OxS) which may be systemic or organ-specific. Although OxS is a consequence of normal body and organ physiology, severely impaired oxidative homeostasis results in DNA hydroxylation, protein denaturation, lipid peroxidation, and apoptosis, ultimately compromising cells’ function and viability. The thyroid gland is an organ that exhibits both oxidative and antioxidative processes. In terms of OxS severity, the thyroid gland’s response could be physiological (i.e. hormone production and secretion) or pathological (i.e. development of diseases, such as goitre, thyroid cancer, or thyroiditis). Protective nutritional antioxidants may benefit defensive antioxidative systems in resolving pro-oxidative dominance and redox imbalance, preventing or delaying chronic thyroid diseases. This review provides information on nutritional antioxidants and their protective roles against impaired redox homeostasis in various thyroid pathologies. We also review novel findings related to the connection between the thyroid gland and gut microbiome and analyze the effects of probiotics with antioxidant properties on thyroid diseases. Copyright © 2023 Macvanin, Gluvic, Zafirovic, Gao, Essack and Isenovic.
T2  - Frontiers in Endocrinology
T1  - The protective role of nutritional antioxidants against oxidative stress in thyroid disorders
VL  - 13
DO  - 10.3389/fendo.2022.1092837
ER  - 

@article{
author = "Mačvanin, Mirjana and Gluvić, Zoran and Zafirović, Sonja and Gao, Xin and Essack, Magbubah and Isenović, Esma R.",
year = "2023",
abstract = "An imbalance between pro-oxidative and antioxidative cellular mechanisms is oxidative stress (OxS) which may be systemic or organ-specific. Although OxS is a consequence of normal body and organ physiology, severely impaired oxidative homeostasis results in DNA hydroxylation, protein denaturation, lipid peroxidation, and apoptosis, ultimately compromising cells’ function and viability. The thyroid gland is an organ that exhibits both oxidative and antioxidative processes. In terms of OxS severity, the thyroid gland’s response could be physiological (i.e. hormone production and secretion) or pathological (i.e. development of diseases, such as goitre, thyroid cancer, or thyroiditis). Protective nutritional antioxidants may benefit defensive antioxidative systems in resolving pro-oxidative dominance and redox imbalance, preventing or delaying chronic thyroid diseases. This review provides information on nutritional antioxidants and their protective roles against impaired redox homeostasis in various thyroid pathologies. We also review novel findings related to the connection between the thyroid gland and gut microbiome and analyze the effects of probiotics with antioxidant properties on thyroid diseases. Copyright © 2023 Macvanin, Gluvic, Zafirovic, Gao, Essack and Isenovic.",
journal = "Frontiers in Endocrinology",
title = "The protective role of nutritional antioxidants against oxidative stress in thyroid disorders",
volume = "13",
doi = "10.3389/fendo.2022.1092837"
}

Mačvanin, M., Gluvić, Z., Zafirović, S., Gao, X., Essack, M.,& Isenović, E. R.. (2023). The protective role of nutritional antioxidants against oxidative stress in thyroid disorders. in Frontiers in Endocrinology, 13.
https://doi.org/10.3389/fendo.2022.1092837

Mačvanin M, Gluvić Z, Zafirović S, Gao X, Essack M, Isenović ER. The protective role of nutritional antioxidants against oxidative stress in thyroid disorders. in Frontiers in Endocrinology. 2023;13.
doi:10.3389/fendo.2022.1092837 .

Mačvanin, Mirjana, Gluvić, Zoran, Zafirović, Sonja, Gao, Xin, Essack, Magbubah, Isenović, Esma R., "The protective role of nutritional antioxidants against oxidative stress in thyroid disorders" in Frontiers in Endocrinology, 13 (2023),
https://doi.org/10.3389/fendo.2022.1092837 . .

TY  - JOUR
AU  - Mačvanin, Mirjana
AU  - Gluvić, Zoran
AU  - Bajić, Vladan
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11574
AB  - Diabetes mellitus (DM) is a group of metabolic disorders defined by hyperglycemia induced by insulin resistance, inadequate insulin secretion, or excessive glucagon secretion. In 2021, the global prevalence of diabetes is anticipated to be 10.7% (537 million people). Noncoding RNAs (ncRNAs) appear to have an important role in the initiation and progression of DM, according to a growing body of research. The two major groups of ncRNAs implicated in diabetic disorders are miRNAs and long noncoding RNAs. miRNAs are singlestranded, short (17–25 nucleotides), ncRNAs that influence gene expression at the post-transcriptional level. Because DM has reached epidemic proportions worldwide, it appears that novel diagnostic and therapeutic strategies are required to identify and treat complications associated with these diseases efficiently. miRNAs are gaining attention as biomarkers for DM diagnosis and potential treatment due to their function in maintaining physiological homeostasis via gene expression regulation. In this review, we address the issue of the gradually expanding global prevalence of DM by presenting a complete and upto-date synopsis of various regulatory miRNAs involved in these disorders. We hope this review will spark discussion about ncRNAs as prognostic biomarkers and therapeutic tools for DM. We examine and synthesize recent research that used novel, high-throughput technologies to uncover ncRNAs involved in DM, necessitating a systematic approach to examining and summarizing their roles and possible diagnostic and therapeutic uses.
T2  - World Journal of Diabetes
T1  - Novel insights regarding the role of noncoding RNAs in diabetes
VL  - 14
IS  - 7
SP  - 958
EP  - 976
DO  - 10.4239/wjd.v14.i7.958
ER  - 

@article{
author = "Mačvanin, Mirjana and Gluvić, Zoran and Bajić, Vladan and Isenović, Esma R.",
year = "2023",
abstract = "Diabetes mellitus (DM) is a group of metabolic disorders defined by hyperglycemia induced by insulin resistance, inadequate insulin secretion, or excessive glucagon secretion. In 2021, the global prevalence of diabetes is anticipated to be 10.7% (537 million people). Noncoding RNAs (ncRNAs) appear to have an important role in the initiation and progression of DM, according to a growing body of research. The two major groups of ncRNAs implicated in diabetic disorders are miRNAs and long noncoding RNAs. miRNAs are singlestranded, short (17–25 nucleotides), ncRNAs that influence gene expression at the post-transcriptional level. Because DM has reached epidemic proportions worldwide, it appears that novel diagnostic and therapeutic strategies are required to identify and treat complications associated with these diseases efficiently. miRNAs are gaining attention as biomarkers for DM diagnosis and potential treatment due to their function in maintaining physiological homeostasis via gene expression regulation. In this review, we address the issue of the gradually expanding global prevalence of DM by presenting a complete and upto-date synopsis of various regulatory miRNAs involved in these disorders. We hope this review will spark discussion about ncRNAs as prognostic biomarkers and therapeutic tools for DM. We examine and synthesize recent research that used novel, high-throughput technologies to uncover ncRNAs involved in DM, necessitating a systematic approach to examining and summarizing their roles and possible diagnostic and therapeutic uses.",
journal = "World Journal of Diabetes",
title = "Novel insights regarding the role of noncoding RNAs in diabetes",
volume = "14",
number = "7",
pages = "958-976",
doi = "10.4239/wjd.v14.i7.958"
}

Mačvanin, M., Gluvić, Z., Bajić, V.,& Isenović, E. R.. (2023). Novel insights regarding the role of noncoding RNAs in diabetes. in World Journal of Diabetes, 14(7), 958-976.
https://doi.org/10.4239/wjd.v14.i7.958

Mačvanin M, Gluvić Z, Bajić V, Isenović ER. Novel insights regarding the role of noncoding RNAs in diabetes. in World Journal of Diabetes. 2023;14(7):958-976.
doi:10.4239/wjd.v14.i7.958 .

Mačvanin, Mirjana, Gluvić, Zoran, Bajić, Vladan, Isenović, Esma R., "Novel insights regarding the role of noncoding RNAs in diabetes" in World Journal of Diabetes, 14, no. 7 (2023):958-976,
https://doi.org/10.4239/wjd.v14.i7.958 . .

TY  - JOUR
AU  - Al-Maini, Mustafa
AU  - Maindarkar, Mahesh
AU  - Kitas, George D.
AU  - Khanna, Narendra N.
AU  - Misra, Durga Prasanna
AU  - Johri, Amer M.
AU  - Mantella, Laura
AU  - Agarwal, Vikas
AU  - Sharma, Aman
AU  - Singh, Inder M.
AU  - Tsoulfas, George
AU  - Laird, John R.
AU  - Faa, Gavino
AU  - Teji, Jagjit
AU  - Turk, Monika
AU  - Visković, Klaudija
AU  - Ruzsa, Zoltan
AU  - Mavrogeni, Sophie
AU  - Rathore, Vijay
AU  - Miner, Martin
AU  - Kalra, Manudeep K.
AU  - Isenović, Esma R.
AU  - Saba, Luca
AU  - Fouda, Mostafa M.
AU  - Suri, Jasjit S.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12947
AB  - The challenges associated with diagnosing and treating cardiovascular disease (CVD)/Stroke in Rheumatoid arthritis (RA) arise from the delayed onset of symptoms. Existing clinical risk scores are inadequate in predicting cardiac events, and conventional risk factors alone do not accurately classify many individuals at risk. Several CVD biomarkers consider the multiple pathways involved in the development of atherosclerosis, which is the primary cause of CVD/Stroke in RA. To enhance the accuracy of CVD/Stroke risk assessment in the RA framework, a proposed approach involves combining genomic-based biomarkers (GBBM) derived from plasma and/or serum samples with innovative non-invasive radiomic-based biomarkers (RBBM), such as measurements of synovial fluid, plaque area, and plaque burden. This review presents two hypotheses: (i) RBBM and GBBM biomarkers exhibit a significant correlation and can precisely detect the severity of CVD/Stroke in RA patients. (ii) Artificial Intelligence (AI)-based preventive, precision, and personalized (aiP3) CVD/Stroke risk AtheroEdge™ model (AtheroPoint™, CA, USA) that utilizes deep learning (DL) to accurately classify the risk of CVD/stroke in RA framework. The authors conducted a comprehensive search using the PRISMA technique, identifying 153 studies that assessed the features/biomarkers of RBBM and GBBM for CVD/Stroke. The study demonstrates how DL models can be integrated into the AtheroEdge™–aiP3 framework to determine the risk of CVD/Stroke in RA patients. The findings of this review suggest that the combination of RBBM with GBBM introduces a new dimension to the assessment of CVD/Stroke risk in the RA framework. Synovial fluid levels that are higher than normal lead to an increase in the plaque burden. Additionally, the review provides recommendations for novel, unbiased, and pruned DL algorithms that can predict CVD/Stroke risk within a RA framework that is preventive, precise, and personalized.
T2  - Rheumatology International
T1  - Artificial intelligence-based preventive, personalized and precision medicine for cardiovascular disease/stroke risk assessment in rheumatoid arthritis patients: a narrative review
VL  - 43
IS  - 11
SP  - 1965
EP  - 1982
DO  - 10.1007/s00296-023-05415-1
ER  - 

@article{
author = "Al-Maini, Mustafa and Maindarkar, Mahesh and Kitas, George D. and Khanna, Narendra N. and Misra, Durga Prasanna and Johri, Amer M. and Mantella, Laura and Agarwal, Vikas and Sharma, Aman and Singh, Inder M. and Tsoulfas, George and Laird, John R. and Faa, Gavino and Teji, Jagjit and Turk, Monika and Visković, Klaudija and Ruzsa, Zoltan and Mavrogeni, Sophie and Rathore, Vijay and Miner, Martin and Kalra, Manudeep K. and Isenović, Esma R. and Saba, Luca and Fouda, Mostafa M. and Suri, Jasjit S.",
year = "2023",
abstract = "The challenges associated with diagnosing and treating cardiovascular disease (CVD)/Stroke in Rheumatoid arthritis (RA) arise from the delayed onset of symptoms. Existing clinical risk scores are inadequate in predicting cardiac events, and conventional risk factors alone do not accurately classify many individuals at risk. Several CVD biomarkers consider the multiple pathways involved in the development of atherosclerosis, which is the primary cause of CVD/Stroke in RA. To enhance the accuracy of CVD/Stroke risk assessment in the RA framework, a proposed approach involves combining genomic-based biomarkers (GBBM) derived from plasma and/or serum samples with innovative non-invasive radiomic-based biomarkers (RBBM), such as measurements of synovial fluid, plaque area, and plaque burden. This review presents two hypotheses: (i) RBBM and GBBM biomarkers exhibit a significant correlation and can precisely detect the severity of CVD/Stroke in RA patients. (ii) Artificial Intelligence (AI)-based preventive, precision, and personalized (aiP3) CVD/Stroke risk AtheroEdge™ model (AtheroPoint™, CA, USA) that utilizes deep learning (DL) to accurately classify the risk of CVD/stroke in RA framework. The authors conducted a comprehensive search using the PRISMA technique, identifying 153 studies that assessed the features/biomarkers of RBBM and GBBM for CVD/Stroke. The study demonstrates how DL models can be integrated into the AtheroEdge™–aiP3 framework to determine the risk of CVD/Stroke in RA patients. The findings of this review suggest that the combination of RBBM with GBBM introduces a new dimension to the assessment of CVD/Stroke risk in the RA framework. Synovial fluid levels that are higher than normal lead to an increase in the plaque burden. Additionally, the review provides recommendations for novel, unbiased, and pruned DL algorithms that can predict CVD/Stroke risk within a RA framework that is preventive, precise, and personalized.",
journal = "Rheumatology International",
title = "Artificial intelligence-based preventive, personalized and precision medicine for cardiovascular disease/stroke risk assessment in rheumatoid arthritis patients: a narrative review",
volume = "43",
number = "11",
pages = "1965-1982",
doi = "10.1007/s00296-023-05415-1"
}

Al-Maini, M., Maindarkar, M., Kitas, G. D., Khanna, N. N., Misra, D. P., Johri, A. M., Mantella, L., Agarwal, V., Sharma, A., Singh, I. M., Tsoulfas, G., Laird, J. R., Faa, G., Teji, J., Turk, M., Visković, K., Ruzsa, Z., Mavrogeni, S., Rathore, V., Miner, M., Kalra, M. K., Isenović, E. R., Saba, L., Fouda, M. M.,& Suri, J. S.. (2023). Artificial intelligence-based preventive, personalized and precision medicine for cardiovascular disease/stroke risk assessment in rheumatoid arthritis patients: a narrative review. in Rheumatology International, 43(11), 1965-1982.
https://doi.org/10.1007/s00296-023-05415-1

Al-Maini M, Maindarkar M, Kitas GD, Khanna NN, Misra DP, Johri AM, Mantella L, Agarwal V, Sharma A, Singh IM, Tsoulfas G, Laird JR, Faa G, Teji J, Turk M, Visković K, Ruzsa Z, Mavrogeni S, Rathore V, Miner M, Kalra MK, Isenović ER, Saba L, Fouda MM, Suri JS. Artificial intelligence-based preventive, personalized and precision medicine for cardiovascular disease/stroke risk assessment in rheumatoid arthritis patients: a narrative review. in Rheumatology International. 2023;43(11):1965-1982.
doi:10.1007/s00296-023-05415-1 .

Al-Maini, Mustafa, Maindarkar, Mahesh, Kitas, George D., Khanna, Narendra N., Misra, Durga Prasanna, Johri, Amer M., Mantella, Laura, Agarwal, Vikas, Sharma, Aman, Singh, Inder M., Tsoulfas, George, Laird, John R., Faa, Gavino, Teji, Jagjit, Turk, Monika, Visković, Klaudija, Ruzsa, Zoltan, Mavrogeni, Sophie, Rathore, Vijay, Miner, Martin, Kalra, Manudeep K., Isenović, Esma R., Saba, Luca, Fouda, Mostafa M., Suri, Jasjit S., "Artificial intelligence-based preventive, personalized and precision medicine for cardiovascular disease/stroke risk assessment in rheumatoid arthritis patients: a narrative review" in Rheumatology International, 43, no. 11 (2023):1965-1982,
https://doi.org/10.1007/s00296-023-05415-1 . .

TY  - JOUR
AU  - Tomasović, M.
AU  - Sinik, M.
AU  - Gluvić, Zoran
AU  - Zafirović, Sonja
AU  - Isenović, Esma
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12878
AB  - Context. Propylthiouracil (PTU) could cause lupus or vasculitis-like hypersensitivities thus interfering with some other concomitant diseases. Objective. Clinicians must be aware of the side effects of medications, particularly after their introduction and long-term use. Some clinical manifestations may be similar to well-known drug side effects or hypersensitivity. Every unusual clinical scenario related to drug use must be evaluated individually and thoroughly. Subjects and Methods. Hands and feet skin changes were observed several days after PTU administration in a male patient with severe diffuse toxic goitre. A complete blood count, biochemistry analyses, thyroid function tests and antibodies, and immunology analyses were performed. Results. As the skin changes were distributed regionally, liver function tests were normal, and there were no signs of clinical deterioration, it was decided to continue PTU treatment and monitor the patient. The initial maculopapular rash quickly turned vesicular, then scaly. After two weeks, the skin changes were wholly restored, with no scarring. Hand, Foot, and Mouth disease (HFMD) was diagnosed after a thorough epidemiological survey and clinical workout. Conclusions. Our case study demonstrates that skin changes associated with HFMD may resemble those associated with PTU-induced vasculitis.
T2  - Acta Endocrinologica (Bucharest)
T1  - Case Report of Hand and Foot Skin Changes Resembling PTU-Induced Vasculitis in a Young Male with Diffuse Toxic Goitre
VL  - 19
IS  - 3
SP  - 380
EP  - 385
DO  - 10.4183/aeb.2023.380
ER  - 

@article{
author = "Tomasović, M. and Sinik, M. and Gluvić, Zoran and Zafirović, Sonja and Isenović, Esma",
year = "2023",
abstract = "Context. Propylthiouracil (PTU) could cause lupus or vasculitis-like hypersensitivities thus interfering with some other concomitant diseases. Objective. Clinicians must be aware of the side effects of medications, particularly after their introduction and long-term use. Some clinical manifestations may be similar to well-known drug side effects or hypersensitivity. Every unusual clinical scenario related to drug use must be evaluated individually and thoroughly. Subjects and Methods. Hands and feet skin changes were observed several days after PTU administration in a male patient with severe diffuse toxic goitre. A complete blood count, biochemistry analyses, thyroid function tests and antibodies, and immunology analyses were performed. Results. As the skin changes were distributed regionally, liver function tests were normal, and there were no signs of clinical deterioration, it was decided to continue PTU treatment and monitor the patient. The initial maculopapular rash quickly turned vesicular, then scaly. After two weeks, the skin changes were wholly restored, with no scarring. Hand, Foot, and Mouth disease (HFMD) was diagnosed after a thorough epidemiological survey and clinical workout. Conclusions. Our case study demonstrates that skin changes associated with HFMD may resemble those associated with PTU-induced vasculitis.",
journal = "Acta Endocrinologica (Bucharest)",
title = "Case Report of Hand and Foot Skin Changes Resembling PTU-Induced Vasculitis in a Young Male with Diffuse Toxic Goitre",
volume = "19",
number = "3",
pages = "380-385",
doi = "10.4183/aeb.2023.380"
}

Tomasović, M., Sinik, M., Gluvić, Z., Zafirović, S.,& Isenović, E.. (2023). Case Report of Hand and Foot Skin Changes Resembling PTU-Induced Vasculitis in a Young Male with Diffuse Toxic Goitre. in Acta Endocrinologica (Bucharest), 19(3), 380-385.
https://doi.org/10.4183/aeb.2023.380

Tomasović M, Sinik M, Gluvić Z, Zafirović S, Isenović E. Case Report of Hand and Foot Skin Changes Resembling PTU-Induced Vasculitis in a Young Male with Diffuse Toxic Goitre. in Acta Endocrinologica (Bucharest). 2023;19(3):380-385.
doi:10.4183/aeb.2023.380 .

Tomasović, M., Sinik, M., Gluvić, Zoran, Zafirović, Sonja, Isenović, Esma, "Case Report of Hand and Foot Skin Changes Resembling PTU-Induced Vasculitis in a Young Male with Diffuse Toxic Goitre" in Acta Endocrinologica (Bucharest), 19, no. 3 (2023):380-385,
https://doi.org/10.4183/aeb.2023.380 . .

TY  - JOUR
AU  - Lukić, Nikola
AU  - Mačvanin, Mirjana T.
AU  - Gluvić, Zoran
AU  - Rizzo, Manfredi
AU  - Radak, Đorđe
AU  - Suri, Jasjit S.
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12022
AB  - Type 2 diabetes mellitus (T2DM) has become a worldwide concern in recent years, primarily in highly developed Western societies. T2DM causes systemic complications, such as atherosclerotic heart disease, ischemic stroke, peripheral artery disease, kidney failure, and diabetes-related maculopathy and retinopathy. The growing number of T2DM patients and the treatment of long-term T2DM-related complications pressurize and exhaust public healthcare systems. As a result, strategies for combating T2DM and developing novel drugs are critical global public health requirements. Aside from preventive measures, which are still the most effective way to prevent T2DM, novel and highly effective therapies are emerging. In the spotlight of next-generation T2DM treatment, sodium-glucose co-transporter 2 (SGLT-2) inhibitors are promoted as the most efficient perspective therapy. SGLT-2 inhibitors (SGLT2i) include phlorizin derivatives, such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT-2, along with SGLT-1, is a member of the SGLT family of proteins that play a role in glucose absorption via active transport mediated by Na+ /K+ ATPase. SGLT-2 is only found in the kidney, specifically the proximal tubule, and is responsible for more than 90% glucose absorption. Inhibition of SGLT-2 reduces glucose absorption, and consequently increases urinary glucose excretion, decreasing blood glucose levels. Thus, the inhibition of SGLT-2 activity ultimately alleviates T2DM-related symptoms and prevents or delays systemic T2DM-associated chronic complications. This review aimed to provide a more detailed understanding of the effects of SGLT2i responsible for the acute improvement in blood glucose regulation, a prerequisite for T2DM-associated cardiovascular complications control.
T2  - Current Medicinal Chemistry
T1  - SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
VL  - 31
DO  - 10.2174/0109298673251493231011192520
ER  - 

@article{
author = "Lukić, Nikola and Mačvanin, Mirjana T. and Gluvić, Zoran and Rizzo, Manfredi and Radak, Đorđe and Suri, Jasjit S. and Isenović, Esma R.",
year = "2023",
abstract = "Type 2 diabetes mellitus (T2DM) has become a worldwide concern in recent years, primarily in highly developed Western societies. T2DM causes systemic complications, such as atherosclerotic heart disease, ischemic stroke, peripheral artery disease, kidney failure, and diabetes-related maculopathy and retinopathy. The growing number of T2DM patients and the treatment of long-term T2DM-related complications pressurize and exhaust public healthcare systems. As a result, strategies for combating T2DM and developing novel drugs are critical global public health requirements. Aside from preventive measures, which are still the most effective way to prevent T2DM, novel and highly effective therapies are emerging. In the spotlight of next-generation T2DM treatment, sodium-glucose co-transporter 2 (SGLT-2) inhibitors are promoted as the most efficient perspective therapy. SGLT-2 inhibitors (SGLT2i) include phlorizin derivatives, such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT-2, along with SGLT-1, is a member of the SGLT family of proteins that play a role in glucose absorption via active transport mediated by Na+ /K+ ATPase. SGLT-2 is only found in the kidney, specifically the proximal tubule, and is responsible for more than 90% glucose absorption. Inhibition of SGLT-2 reduces glucose absorption, and consequently increases urinary glucose excretion, decreasing blood glucose levels. Thus, the inhibition of SGLT-2 activity ultimately alleviates T2DM-related symptoms and prevents or delays systemic T2DM-associated chronic complications. This review aimed to provide a more detailed understanding of the effects of SGLT2i responsible for the acute improvement in blood glucose regulation, a prerequisite for T2DM-associated cardiovascular complications control.",
journal = "Current Medicinal Chemistry",
title = "SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus",
volume = "31",
doi = "10.2174/0109298673251493231011192520"
}

Lukić, N., Mačvanin, M. T., Gluvić, Z., Rizzo, M., Radak, Đ., Suri, J. S.,& Isenović, E. R.. (2023). SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus. in Current Medicinal Chemistry, 31.
https://doi.org/10.2174/0109298673251493231011192520

Lukić N, Mačvanin MT, Gluvić Z, Rizzo M, Radak Đ, Suri JS, Isenović ER. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus. in Current Medicinal Chemistry. 2023;31.
doi:10.2174/0109298673251493231011192520 .

Lukić, Nikola, Mačvanin, Mirjana T., Gluvić, Zoran, Rizzo, Manfredi, Radak, Đorđe, Suri, Jasjit S., Isenović, Esma R., "SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus" in Current Medicinal Chemistry, 31 (2023),
https://doi.org/10.2174/0109298673251493231011192520 . .

TY  - JOUR
AU  - Petrović, Nina
AU  - Essack, Magbubah
AU  - Šami, Ahmad
AU  - Perry, George
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
AU  - Bajić, Vladan P.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11351
AB  - MicroRNAs (miRNAs) are involved in the regulation of various cellular processes including pathological conditions. MiRNA networks have been extensively researched in age-related degenerative diseases, such as cancer, Alzheimer’s disease (AD), and heart failure. Thus, miRNA has been studied from different approaches, in vivo, in vitro, and in silico including miRNA networks. Networks linking diverse biomedical entities unveil information not readily observable by other means. This work focuses on biological networks related to Breast cancer susceptibility 1 (BRCA1) in AD and breast cancer (BC). Using various bioinformatics approaches, we identified subnetworks common to AD and BC that suggest they are linked. According to our results, miR-107 was identified as a potentially good candidate for both AD and BC treatment (targeting BRCA1/2 and PTEN in both diseases), accompanied by miR-146a and miR-17. The analysis also confirmed the involvement of the miR-17-92 cluster, and miR-124-3p, and highlighted the importance of poorly researched miRNAs such as mir-6785 mir6127, mir-6870, or miR-8485. After filtering the in silico analysis results, we found 49 miRNA molecules that modulate the expression of at least five genes common to both BC and AD. Those 49 miRNAs regulate the expression of 122 genes in AD and 93 genes in BC, from which 26 genes are common genes for AD and BC involved in neuron differentiation and genesis, cell differentiation and migration, regulation of cell cycle, and cancer development. Additionally, the highly enriched pathway was associated with diabetic complications, pointing out possible interplay among molecules underlying BC, AD, and diabetes pathology
T2  - Computational Biology and Chemistry
T1  - MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment
VL  - 106
SP  - 107925
DO  - 10.1016/j.compbiolchem.2023.107925
ER  - 

@article{
author = "Petrović, Nina and Essack, Magbubah and Šami, Ahmad and Perry, George and Gojobori, Takashi and Isenović, Esma R. and Bajić, Vladan P.",
year = "2023",
abstract = "MicroRNAs (miRNAs) are involved in the regulation of various cellular processes including pathological conditions. MiRNA networks have been extensively researched in age-related degenerative diseases, such as cancer, Alzheimer’s disease (AD), and heart failure. Thus, miRNA has been studied from different approaches, in vivo, in vitro, and in silico including miRNA networks. Networks linking diverse biomedical entities unveil information not readily observable by other means. This work focuses on biological networks related to Breast cancer susceptibility 1 (BRCA1) in AD and breast cancer (BC). Using various bioinformatics approaches, we identified subnetworks common to AD and BC that suggest they are linked. According to our results, miR-107 was identified as a potentially good candidate for both AD and BC treatment (targeting BRCA1/2 and PTEN in both diseases), accompanied by miR-146a and miR-17. The analysis also confirmed the involvement of the miR-17-92 cluster, and miR-124-3p, and highlighted the importance of poorly researched miRNAs such as mir-6785 mir6127, mir-6870, or miR-8485. After filtering the in silico analysis results, we found 49 miRNA molecules that modulate the expression of at least five genes common to both BC and AD. Those 49 miRNAs regulate the expression of 122 genes in AD and 93 genes in BC, from which 26 genes are common genes for AD and BC involved in neuron differentiation and genesis, cell differentiation and migration, regulation of cell cycle, and cancer development. Additionally, the highly enriched pathway was associated with diabetic complications, pointing out possible interplay among molecules underlying BC, AD, and diabetes pathology",
journal = "Computational Biology and Chemistry",
title = "MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment",
volume = "106",
pages = "107925",
doi = "10.1016/j.compbiolchem.2023.107925"
}

Petrović, N., Essack, M., Šami, A., Perry, G., Gojobori, T., Isenović, E. R.,& Bajić, V. P.. (2023). MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment. in Computational Biology and Chemistry, 106, 107925.
https://doi.org/10.1016/j.compbiolchem.2023.107925

Petrović N, Essack M, Šami A, Perry G, Gojobori T, Isenović ER, Bajić VP. MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment. in Computational Biology and Chemistry. 2023;106:107925.
doi:10.1016/j.compbiolchem.2023.107925 .

Petrović, Nina, Essack, Magbubah, Šami, Ahmad, Perry, George, Gojobori, Takashi, Isenović, Esma R., Bajić, Vladan P., "MicroRNA networks linked with BRCA1/2, PTEN, and common genes for Alzheimer's disease and breast cancer share highly enriched pathways that may unravel targets for the AD/BC comorbidity treatment" in Computational Biology and Chemistry, 106 (2023):107925,
https://doi.org/10.1016/j.compbiolchem.2023.107925 . .

TY  - JOUR
AU  - Mačvanin, Mirjana T.
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12025
AB  - Diabetes mellitus (DM) refers to a complex cluster of metabolic disorders characterized by hyperglycemia caused by inadequate insulin secretion, insulin resistance, or excessive glucagon secretion. If not correctly treated, the prolonged effects of DM-associated metabolic perturbations lead to systemic vascular complications and cardiovascular disease (CVD), the principal cause of mortality among patients with DM. Given the increase in the global prevalence of diabetes, novel diagnostic and therapeutic procedures are necessary for its effective identification and treatment. Recent findings point to an important role of microRNA (miRNAs) in DM initiation and progression, as well as the occurrence of associated cardiovascular complications. miRNAs are short, highly conserved, single-stranded, non-coding RNAs that contribute to the maintenance of physiological homeostasis through the regulation of crucial processes such as metabolism, cell proliferation, and apoptosis. The increased availability of high-throughput methodologies for identifying and characterizing non-coding RNAs has led to considerable interest in miRNAs as potential biomarkers and therapeutic agents for DM. In this review, we first comprehensively detail the regulatory miRNAs involved in the pathophysiology of DM and diabetic cardiomyopathy (DCMP). Subsequently, we summarize findings regarding the utility of several of these miRNAs as potential prognostic and diagnostic biomarkers for DM and DM-associated CVD. Finally, we evaluate the potential of miRNA-based therapeutic approaches for treating DM and DCMP in the clinical setting.
T2  - Cardiology Plus
T1  - Diabetes and associated cardiovascular complications: The role of microRNAs
VL  - 8
IS  - 3
SP  - 167
EP  - 183
DO  - 10.1097/CP9.0000000000000062
ER  - 

@article{
author = "Mačvanin, Mirjana T. and Isenović, Esma R.",
year = "2023",
abstract = "Diabetes mellitus (DM) refers to a complex cluster of metabolic disorders characterized by hyperglycemia caused by inadequate insulin secretion, insulin resistance, or excessive glucagon secretion. If not correctly treated, the prolonged effects of DM-associated metabolic perturbations lead to systemic vascular complications and cardiovascular disease (CVD), the principal cause of mortality among patients with DM. Given the increase in the global prevalence of diabetes, novel diagnostic and therapeutic procedures are necessary for its effective identification and treatment. Recent findings point to an important role of microRNA (miRNAs) in DM initiation and progression, as well as the occurrence of associated cardiovascular complications. miRNAs are short, highly conserved, single-stranded, non-coding RNAs that contribute to the maintenance of physiological homeostasis through the regulation of crucial processes such as metabolism, cell proliferation, and apoptosis. The increased availability of high-throughput methodologies for identifying and characterizing non-coding RNAs has led to considerable interest in miRNAs as potential biomarkers and therapeutic agents for DM. In this review, we first comprehensively detail the regulatory miRNAs involved in the pathophysiology of DM and diabetic cardiomyopathy (DCMP). Subsequently, we summarize findings regarding the utility of several of these miRNAs as potential prognostic and diagnostic biomarkers for DM and DM-associated CVD. Finally, we evaluate the potential of miRNA-based therapeutic approaches for treating DM and DCMP in the clinical setting.",
journal = "Cardiology Plus",
title = "Diabetes and associated cardiovascular complications: The role of microRNAs",
volume = "8",
number = "3",
pages = "167-183",
doi = "10.1097/CP9.0000000000000062"
}

Mačvanin, M. T.,& Isenović, E. R.. (2023). Diabetes and associated cardiovascular complications: The role of microRNAs. in Cardiology Plus, 8(3), 167-183.
https://doi.org/10.1097/CP9.0000000000000062

Mačvanin MT, Isenović ER. Diabetes and associated cardiovascular complications: The role of microRNAs. in Cardiology Plus. 2023;8(3):167-183.
doi:10.1097/CP9.0000000000000062 .

Mačvanin, Mirjana T., Isenović, Esma R., "Diabetes and associated cardiovascular complications: The role of microRNAs" in Cardiology Plus, 8, no. 3 (2023):167-183,
https://doi.org/10.1097/CP9.0000000000000062 . .

TY  - JOUR
AU  - Khanna, Narendra N
AU  - Singh, Manasvi
AU  - Maindarkar, Mahesh
AU  - Kumar, Ashish
AU  - Johri, Amer M.
AU  - Mentella, Laura
AU  - Laird, John R
AU  - Paraskevas, Kosmas I.
AU  - Ruzsa, Zoltan
AU  - Singh, Narpinder
AU  - Kalra, Mannudeep K.
AU  - Fernandes, Jose Fernandes E.
AU  - Chaturvedi, Seemant
AU  - Nicolaides, Andrew
AU  - Rathore, Vijay
AU  - Singh, Inder
AU  - Teji, Jagjit S.
AU  - Al-Maini, Mostafa
AU  - Isenović, Esma R.
AU  - Viswanathan, Vijay
AU  - Khanna, Puneet
AU  - Fouda, Mostafa M.
AU  - Saba, Luca
AU  - Suri, Jasjit S.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12112
AB  - Cardiovascular disease (CVD) related mortality and morbidity heavily strain society. The relationship between external risk factors and our genetics have not been well established. It is widely acknowledged that environmental influence and individual behaviours play a significant role in CVD vulnerability, leading to the development of polygenic risk scores (PRS). We employed the PRISMA search method to locate pertinent research and literature to extensively review artificial intelligence (AI)-based PRS models for CVD risk prediction. Furthermore, we analyzed and compared conventional vs. AI-based solutions for PRS. We summarized the recent advances in our understanding of the use of AI-based PRS for risk prediction of CVD. Our study proposes three hypotheses: i) Multiple genetic variations and risk factors can be incorporated into AI-based PRS to improve the accuracy of CVD risk predicting. ii) AI-based PRS for CVD circumvents the drawbacks of conventional PRS calculators by incorporating a larger variety of genetic and non-genetic components, allowing for more precise and individualised risk estimations. iii) Using AI approaches, it is possible to significantly reduce the dimensionality of huge genomic datasets, resulting in more accurate and effective disease risk prediction models. Our study highlighted that the AI-PRS model outperformed traditional PRS calculators in predicting CVD risk. Furthermore, using AI-based methods to calculate PRS may increase the precision of risk predictions for CVD and have significant ramifications for individualized prevention and treatment plans.
T2  - Journal of Korean Medical Science
T1  - Polygenic Risk Score for Cardiovascular Diseases in Artificial Intelligence Paradigm: A Review
VL  - 38
IS  - 46
DO  - 10.3346/jkms.2023.38.e395
ER  - 

@article{
author = "Khanna, Narendra N and Singh, Manasvi and Maindarkar, Mahesh and Kumar, Ashish and Johri, Amer M. and Mentella, Laura and Laird, John R and Paraskevas, Kosmas I. and Ruzsa, Zoltan and Singh, Narpinder and Kalra, Mannudeep K. and Fernandes, Jose Fernandes E. and Chaturvedi, Seemant and Nicolaides, Andrew and Rathore, Vijay and Singh, Inder and Teji, Jagjit S. and Al-Maini, Mostafa and Isenović, Esma R. and Viswanathan, Vijay and Khanna, Puneet and Fouda, Mostafa M. and Saba, Luca and Suri, Jasjit S.",
year = "2023",
abstract = "Cardiovascular disease (CVD) related mortality and morbidity heavily strain society. The relationship between external risk factors and our genetics have not been well established. It is widely acknowledged that environmental influence and individual behaviours play a significant role in CVD vulnerability, leading to the development of polygenic risk scores (PRS). We employed the PRISMA search method to locate pertinent research and literature to extensively review artificial intelligence (AI)-based PRS models for CVD risk prediction. Furthermore, we analyzed and compared conventional vs. AI-based solutions for PRS. We summarized the recent advances in our understanding of the use of AI-based PRS for risk prediction of CVD. Our study proposes three hypotheses: i) Multiple genetic variations and risk factors can be incorporated into AI-based PRS to improve the accuracy of CVD risk predicting. ii) AI-based PRS for CVD circumvents the drawbacks of conventional PRS calculators by incorporating a larger variety of genetic and non-genetic components, allowing for more precise and individualised risk estimations. iii) Using AI approaches, it is possible to significantly reduce the dimensionality of huge genomic datasets, resulting in more accurate and effective disease risk prediction models. Our study highlighted that the AI-PRS model outperformed traditional PRS calculators in predicting CVD risk. Furthermore, using AI-based methods to calculate PRS may increase the precision of risk predictions for CVD and have significant ramifications for individualized prevention and treatment plans.",
journal = "Journal of Korean Medical Science",
title = "Polygenic Risk Score for Cardiovascular Diseases in Artificial Intelligence Paradigm: A Review",
volume = "38",
number = "46",
doi = "10.3346/jkms.2023.38.e395"
}

Khanna, N. N., Singh, M., Maindarkar, M., Kumar, A., Johri, A. M., Mentella, L., Laird, J. R., Paraskevas, K. I., Ruzsa, Z., Singh, N., Kalra, M. K., Fernandes, J. F. E., Chaturvedi, S., Nicolaides, A., Rathore, V., Singh, I., Teji, J. S., Al-Maini, M., Isenović, E. R., Viswanathan, V., Khanna, P., Fouda, M. M., Saba, L.,& Suri, J. S.. (2023). Polygenic Risk Score for Cardiovascular Diseases in Artificial Intelligence Paradigm: A Review. in Journal of Korean Medical Science, 38(46).
https://doi.org/10.3346/jkms.2023.38.e395

Khanna NN, Singh M, Maindarkar M, Kumar A, Johri AM, Mentella L, Laird JR, Paraskevas KI, Ruzsa Z, Singh N, Kalra MK, Fernandes JFE, Chaturvedi S, Nicolaides A, Rathore V, Singh I, Teji JS, Al-Maini M, Isenović ER, Viswanathan V, Khanna P, Fouda MM, Saba L, Suri JS. Polygenic Risk Score for Cardiovascular Diseases in Artificial Intelligence Paradigm: A Review. in Journal of Korean Medical Science. 2023;38(46).
doi:10.3346/jkms.2023.38.e395 .

Khanna, Narendra N, Singh, Manasvi, Maindarkar, Mahesh, Kumar, Ashish, Johri, Amer M., Mentella, Laura, Laird, John R, Paraskevas, Kosmas I., Ruzsa, Zoltan, Singh, Narpinder, Kalra, Mannudeep K., Fernandes, Jose Fernandes E., Chaturvedi, Seemant, Nicolaides, Andrew, Rathore, Vijay, Singh, Inder, Teji, Jagjit S., Al-Maini, Mostafa, Isenović, Esma R., Viswanathan, Vijay, Khanna, Puneet, Fouda, Mostafa M., Saba, Luca, Suri, Jasjit S., "Polygenic Risk Score for Cardiovascular Diseases in Artificial Intelligence Paradigm: A Review" in Journal of Korean Medical Science, 38, no. 46 (2023),
https://doi.org/10.3346/jkms.2023.38.e395 . .

TY  - JOUR
AU  - Zarić, Božidarka
AU  - Mačvanin, Mirjana
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10562
AB  - Reactive species are highly-reactive enzymatically, or non-enzymatically produced compounds with important roles in physiological and pathophysiological cellular processes. Although reactive species represent an extensively researched topic in biomedical sciences, many aspects of their roles and functions remain unclear. This review aims to systematically summarize findings regarding the biochemical characteristics of various types of reactive species and specify the localization and mechanisms of their production in cells. In addition, we discuss the specific roles of free radicals in cellular physiology, focusing on the current lines of research that aim to identify the reactive oxygen species-initiated cascades of reactions resulting in adaptive or pathological cellular responses. Finally, we present recent findings regarding the therapeutic modulations of intracellular levels of reactive oxygen species, which may have substantial significance in developing novel agents for treating several diseases.
T2  - The International Journal of Biochemistry and Cell Biology
T1  - Free radicals: Relationship to Human Diseases and Potential Therapeutic applications
VL  - 154
SP  - 106346
DO  - 10.1016/j.biocel.2022.106346
ER  - 

@article{
author = "Zarić, Božidarka and Mačvanin, Mirjana and Isenović, Esma R.",
year = "2023",
abstract = "Reactive species are highly-reactive enzymatically, or non-enzymatically produced compounds with important roles in physiological and pathophysiological cellular processes. Although reactive species represent an extensively researched topic in biomedical sciences, many aspects of their roles and functions remain unclear. This review aims to systematically summarize findings regarding the biochemical characteristics of various types of reactive species and specify the localization and mechanisms of their production in cells. In addition, we discuss the specific roles of free radicals in cellular physiology, focusing on the current lines of research that aim to identify the reactive oxygen species-initiated cascades of reactions resulting in adaptive or pathological cellular responses. Finally, we present recent findings regarding the therapeutic modulations of intracellular levels of reactive oxygen species, which may have substantial significance in developing novel agents for treating several diseases.",
journal = "The International Journal of Biochemistry and Cell Biology",
title = "Free radicals: Relationship to Human Diseases and Potential Therapeutic applications",
volume = "154",
pages = "106346",
doi = "10.1016/j.biocel.2022.106346"
}

Zarić, B., Mačvanin, M.,& Isenović, E. R.. (2023). Free radicals: Relationship to Human Diseases and Potential Therapeutic applications. in The International Journal of Biochemistry and Cell Biology, 154, 106346.
https://doi.org/10.1016/j.biocel.2022.106346

Zarić B, Mačvanin M, Isenović ER. Free radicals: Relationship to Human Diseases and Potential Therapeutic applications. in The International Journal of Biochemistry and Cell Biology. 2023;154:106346.
doi:10.1016/j.biocel.2022.106346 .

Zarić, Božidarka, Mačvanin, Mirjana, Isenović, Esma R., "Free radicals: Relationship to Human Diseases and Potential Therapeutic applications" in The International Journal of Biochemistry and Cell Biology, 154 (2023):106346,
https://doi.org/10.1016/j.biocel.2022.106346 . .

TY  - JOUR
AU  - Alamro, Hind
AU  - Bajić, Vladan P.
AU  - Mačvanin, Mirjana
AU  - Isenović, Esma R.
AU  - Gojobori, Takashi
AU  - Essack, Magbubah
AU  - Gao, Xin
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10628
AB  - MicroRNAs (miRNAs) are critical regulators of gene expression in healthy and diseased states, and numerous studies have established their tremendous potential as a tool for improving the diagnosis of Type 2 Diabetes Mellitus (T2D) and its comorbidities. In this regard, we computationally identify novel top-ranked hub miRNAs that might be involved in T2D. We accomplish this via two strategies: 1) by ranking miRNAs based on the number of T2D differentially expressed genes (DEGs) they target, and 2) using only the common DEGs between T2D and its comorbidity, Alzheimer’s disease (AD) to predict and rank miRNA. Then classifier models are built using the DEGs targeted by each miRNA as features. Here, we show the T2D DEGs targeted by hsa-mir-1-3p, hsa-mir-16-5p, hsa-mir-124-3p, hsa-mir-34a-5p, hsa-let-7b-5p, hsa-mir-155-5p, hsa-mir-107, hsa-mir-27a-3p, hsa-mir-129-2-3p, and hsa-mir-146a-5p are capable of distinguishing T2D samples from the controls, which serves as a measure of confidence in the miRNAs’ potential role in T2D progression. Moreover, for the second strategy, we show other critical miRNAs can be made apparent through the disease’s comorbidities, and in this case, overall, the hsa-mir-103a-3p models work well for all the datasets, especially in T2D, while the hsa-mir-124-3p models achieved the best scores for the AD datasets. To the best of our knowledge, this is the first study that used predicted miRNAs to determine the features that can separate the diseased samples (T2D or AD) from the normal ones, instead of using conventional non-biology-based feature selection methods.
T2  - Frontiers in Endocrinology
T1  - Type 2 Diabetes Mellitus and its comorbidity, Alzheimer’s disease: Identifying critical microRNA using machine learning
VL  - 13
SP  - 1084656
DO  - 10.3389/fendo.2022.1084656
ER  - 

@article{
author = "Alamro, Hind and Bajić, Vladan P. and Mačvanin, Mirjana and Isenović, Esma R. and Gojobori, Takashi and Essack, Magbubah and Gao, Xin",
year = "2023",
abstract = "MicroRNAs (miRNAs) are critical regulators of gene expression in healthy and diseased states, and numerous studies have established their tremendous potential as a tool for improving the diagnosis of Type 2 Diabetes Mellitus (T2D) and its comorbidities. In this regard, we computationally identify novel top-ranked hub miRNAs that might be involved in T2D. We accomplish this via two strategies: 1) by ranking miRNAs based on the number of T2D differentially expressed genes (DEGs) they target, and 2) using only the common DEGs between T2D and its comorbidity, Alzheimer’s disease (AD) to predict and rank miRNA. Then classifier models are built using the DEGs targeted by each miRNA as features. Here, we show the T2D DEGs targeted by hsa-mir-1-3p, hsa-mir-16-5p, hsa-mir-124-3p, hsa-mir-34a-5p, hsa-let-7b-5p, hsa-mir-155-5p, hsa-mir-107, hsa-mir-27a-3p, hsa-mir-129-2-3p, and hsa-mir-146a-5p are capable of distinguishing T2D samples from the controls, which serves as a measure of confidence in the miRNAs’ potential role in T2D progression. Moreover, for the second strategy, we show other critical miRNAs can be made apparent through the disease’s comorbidities, and in this case, overall, the hsa-mir-103a-3p models work well for all the datasets, especially in T2D, while the hsa-mir-124-3p models achieved the best scores for the AD datasets. To the best of our knowledge, this is the first study that used predicted miRNAs to determine the features that can separate the diseased samples (T2D or AD) from the normal ones, instead of using conventional non-biology-based feature selection methods.",
journal = "Frontiers in Endocrinology",
title = "Type 2 Diabetes Mellitus and its comorbidity, Alzheimer’s disease: Identifying critical microRNA using machine learning",
volume = "13",
pages = "1084656",
doi = "10.3389/fendo.2022.1084656"
}

Alamro, H., Bajić, V. P., Mačvanin, M., Isenović, E. R., Gojobori, T., Essack, M.,& Gao, X.. (2023). Type 2 Diabetes Mellitus and its comorbidity, Alzheimer’s disease: Identifying critical microRNA using machine learning. in Frontiers in Endocrinology, 13, 1084656.
https://doi.org/10.3389/fendo.2022.1084656

Alamro H, Bajić VP, Mačvanin M, Isenović ER, Gojobori T, Essack M, Gao X. Type 2 Diabetes Mellitus and its comorbidity, Alzheimer’s disease: Identifying critical microRNA using machine learning. in Frontiers in Endocrinology. 2023;13:1084656.
doi:10.3389/fendo.2022.1084656 .

Alamro, Hind, Bajić, Vladan P., Mačvanin, Mirjana, Isenović, Esma R., Gojobori, Takashi, Essack, Magbubah, Gao, Xin, "Type 2 Diabetes Mellitus and its comorbidity, Alzheimer’s disease: Identifying critical microRNA using machine learning" in Frontiers in Endocrinology, 13 (2023):1084656,
https://doi.org/10.3389/fendo.2022.1084656 . .

TY  - JOUR
AU  - Mačvanin, Mirjana
AU  - Gluvić, Zoran
AU  - Radovanović, Jelena
AU  - Essack, Magbubah
AU  - Gao, Xin
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10686
AB  - Cardiovascular (CV) disorders are steadily increasing, making them the world’s most prevalent health issue. New research highlights the importance of insulin-like growth factor 1 (IGF-1) for maintaining CV healthMethodsWe searched PubMed and MEDLINE for English and non-English articles with English abstracts published between 1957 (when the first report on IGF-1 identification was published) and 2022. The top search terms were: IGF-1, cardiovascular disease, IGF-1 receptors, IGF-1 and microRNAs, therapeutic interventions with IGF-1, IGF-1 and diabetes, IGF-1 and cardiovascular disease. The search retrieved original peer-reviewed articles, which were further analyzed, focusing on the role of IGF-1 in pathophysiological conditions. We specifically focused on including the most recent findings published in the past five years.ResultsIGF-1, an anabolic growth factor, regulates cell division, proliferation, and survival. In addition to its well-known growth-promoting and metabolic effects, there is mounting evidence that IGF-1 plays a specialized role in the complex activities that underpin CV function. IGF-1 promotes cardiac development and improves cardiac output, stroke volume, contractility, and ejection fraction. Furthermore, IGF-1 mediates many growth hormones (GH) actions. IGF-1 stimulates contractility and tissue remodeling in humans to improve heart function after myocardial infarction. IGF-1 also improves the lipid profile, lowers insulin levels, increases insulin sensitivity, and promotes glucose metabolism. These findings point to the intriguing medicinal potential of IGF-1. Human studies associate low serum levels of free or total IGF-1 with an increased risk of CV and cerebrovascular illness. Extensive human trials are being conducted to investigate the therapeutic efficacy and outcomes of IGF-1-related therapy.DiscussionWe anticipate the development of novel IGF-1-related therapy with minimal side effects. This review discusses recent findings on the role of IGF-1 in the cardiovascular (CVD) system, including both normal and pathological conditions. We also discuss progress in therapeutic interventions aimed at targeting the IGF axis and provide insights into the epigenetic regulation of IGF-1 mediated by microRNAs.
T2  - Frontiers in Endocrinology
T1  - New insights on the cardiovascular effects of IGF-1
VL  - 14
SP  - 1142644
DO  - 10.3389/fendo.2023.1142644
ER  - 

@article{
author = "Mačvanin, Mirjana and Gluvić, Zoran and Radovanović, Jelena and Essack, Magbubah and Gao, Xin and Isenović, Esma R.",
year = "2023",
abstract = "Cardiovascular (CV) disorders are steadily increasing, making them the world’s most prevalent health issue. New research highlights the importance of insulin-like growth factor 1 (IGF-1) for maintaining CV healthMethodsWe searched PubMed and MEDLINE for English and non-English articles with English abstracts published between 1957 (when the first report on IGF-1 identification was published) and 2022. The top search terms were: IGF-1, cardiovascular disease, IGF-1 receptors, IGF-1 and microRNAs, therapeutic interventions with IGF-1, IGF-1 and diabetes, IGF-1 and cardiovascular disease. The search retrieved original peer-reviewed articles, which were further analyzed, focusing on the role of IGF-1 in pathophysiological conditions. We specifically focused on including the most recent findings published in the past five years.ResultsIGF-1, an anabolic growth factor, regulates cell division, proliferation, and survival. In addition to its well-known growth-promoting and metabolic effects, there is mounting evidence that IGF-1 plays a specialized role in the complex activities that underpin CV function. IGF-1 promotes cardiac development and improves cardiac output, stroke volume, contractility, and ejection fraction. Furthermore, IGF-1 mediates many growth hormones (GH) actions. IGF-1 stimulates contractility and tissue remodeling in humans to improve heart function after myocardial infarction. IGF-1 also improves the lipid profile, lowers insulin levels, increases insulin sensitivity, and promotes glucose metabolism. These findings point to the intriguing medicinal potential of IGF-1. Human studies associate low serum levels of free or total IGF-1 with an increased risk of CV and cerebrovascular illness. Extensive human trials are being conducted to investigate the therapeutic efficacy and outcomes of IGF-1-related therapy.DiscussionWe anticipate the development of novel IGF-1-related therapy with minimal side effects. This review discusses recent findings on the role of IGF-1 in the cardiovascular (CVD) system, including both normal and pathological conditions. We also discuss progress in therapeutic interventions aimed at targeting the IGF axis and provide insights into the epigenetic regulation of IGF-1 mediated by microRNAs.",
journal = "Frontiers in Endocrinology",
title = "New insights on the cardiovascular effects of IGF-1",
volume = "14",
pages = "1142644",
doi = "10.3389/fendo.2023.1142644"
}

Mačvanin, M., Gluvić, Z., Radovanović, J., Essack, M., Gao, X.,& Isenović, E. R.. (2023). New insights on the cardiovascular effects of IGF-1. in Frontiers in Endocrinology, 14, 1142644.
https://doi.org/10.3389/fendo.2023.1142644

Mačvanin M, Gluvić Z, Radovanović J, Essack M, Gao X, Isenović ER. New insights on the cardiovascular effects of IGF-1. in Frontiers in Endocrinology. 2023;14:1142644.
doi:10.3389/fendo.2023.1142644 .

Mačvanin, Mirjana, Gluvić, Zoran, Radovanović, Jelena, Essack, Magbubah, Gao, Xin, Isenović, Esma R., "New insights on the cardiovascular effects of IGF-1" in Frontiers in Endocrinology, 14 (2023):1142644,
https://doi.org/10.3389/fendo.2023.1142644 . .

TY  - JOUR
AU  - Mačvanin, Mirjana
AU  - Zafirović, Sonja
AU  - Obradović, Milan M.
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10687
T2  - Frontiers in Endocrinology
T1  - Editorial: Non-coding RNA in diabetes and cardiovascular diseases
VL  - 14
DO  - 10.3389/fendo.2023.1149857
ER  - 

@article{
author = "Mačvanin, Mirjana and Zafirović, Sonja and Obradović, Milan M. and Isenović, Esma R.",
year = "2023",
journal = "Frontiers in Endocrinology",
title = "Editorial: Non-coding RNA in diabetes and cardiovascular diseases",
volume = "14",
doi = "10.3389/fendo.2023.1149857"
}

Mačvanin, M., Zafirović, S., Obradović, M. M.,& Isenović, E. R.. (2023). Editorial: Non-coding RNA in diabetes and cardiovascular diseases. in Frontiers in Endocrinology, 14.
https://doi.org/10.3389/fendo.2023.1149857

Mačvanin M, Zafirović S, Obradović MM, Isenović ER. Editorial: Non-coding RNA in diabetes and cardiovascular diseases. in Frontiers in Endocrinology. 2023;14.
doi:10.3389/fendo.2023.1149857 .

Mačvanin, Mirjana, Zafirović, Sonja, Obradović, Milan M., Isenović, Esma R., "Editorial: Non-coding RNA in diabetes and cardiovascular diseases" in Frontiers in Endocrinology, 14 (2023),
https://doi.org/10.3389/fendo.2023.1149857 . .

TY  - JOUR
AU  - Panić, Anastasija
AU  - Sudar-Milovanović, Emina
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Soskić, Sanja S.
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10744
AB  - The liver is an organ in which many oxidative processes occur and represents an important target of oxidative stress (OxS). Under physiological conditions of normal mitochondrial homeostasis, hepatocytes effectively remove reactive oxygen species (ROS) by enabling metabolic adaptations and through the antioxidant defence system mechanisms. However, obesity-induced lipid accumulation in the hepatocytes causes significantly elevated production of ROS, reduces oxidative capacity, and increases oxidative stress (OxS). In men, compared with premenopausal women, the development of insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD) in obesity are more prevalent, where oestradiol (E2), the most potent female sex steroid, is proposed as the main culprit. Exogenous oestradiol (E2) administration exerts beneficial effects on antioxidant properties, restores total plasma antioxidant capacity and decreases biomarkers of OxS in ovariectomized animal models. Thus, we hypothesized that E2 treatment in states of obesity could have beneficial effects against OxS in the obese male's liver. We assumed that E2 could directly affect the level of OxS by increasing the level/activity of the AOS enzymes, particularly SOD1, SOD2, GPx, and CAT, in obese males' livers. In addition, we assumed that the level of malondialdehyde (MDA) and protein carbonyl content (PCC) in obese males' livers would be reduced after E2 treatment as a result of E2 inhibitory effect on lipid peroxidation and protein oxidation, respectively. To test our hypothesis, we used the liver of a high-fat (HF) diet-fed male Wistar rats as an animal model of obesity, treated with E2 intraperitoneally (40 μg/kg). Preliminary results from this study support our hypothesis that E2 increases liver protein expression of AOS enzymes: SOD1, GPx, and CAT, in control and HF male rats compared with their respective controls. The protein level of SOD2 and CAT activity was increased in HF treated with E2 compared with non-treated HF rats. Moreover, as we expected, E2 administration significantly decreased the MDA level in both E2-treated groups compared to their controls, while the PCC level was significantly decreased in HF treated group compared with untreated HF rats. In conclusion, the preliminary results we obtained in this study indicate that E2 administration can effectively inhibit the OxS-related processes in the liver in HF diet-induced obesity by increasing AOS enzymes levels and CAT activity, and also by decreasing levels of MDA and PCC. A consequence of our hypothesis is that treatment with E2 may be an innovative way to improve obesity-related liver disease prevention and healing. © 2023 Elsevier Ltd
T2  - Medical Hypotheses
T1  - Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?
VL  - 174
SP  - 111049
DO  - 10.1016/j.mehy.2023.111049
ER  - 

@article{
author = "Panić, Anastasija and Sudar-Milovanović, Emina and Stanimirović, Julijana and Obradović, Milan M. and Zafirović, Sonja and Soskić, Sanja S. and Isenović, Esma R.",
year = "2023",
abstract = "The liver is an organ in which many oxidative processes occur and represents an important target of oxidative stress (OxS). Under physiological conditions of normal mitochondrial homeostasis, hepatocytes effectively remove reactive oxygen species (ROS) by enabling metabolic adaptations and through the antioxidant defence system mechanisms. However, obesity-induced lipid accumulation in the hepatocytes causes significantly elevated production of ROS, reduces oxidative capacity, and increases oxidative stress (OxS). In men, compared with premenopausal women, the development of insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD) in obesity are more prevalent, where oestradiol (E2), the most potent female sex steroid, is proposed as the main culprit. Exogenous oestradiol (E2) administration exerts beneficial effects on antioxidant properties, restores total plasma antioxidant capacity and decreases biomarkers of OxS in ovariectomized animal models. Thus, we hypothesized that E2 treatment in states of obesity could have beneficial effects against OxS in the obese male's liver. We assumed that E2 could directly affect the level of OxS by increasing the level/activity of the AOS enzymes, particularly SOD1, SOD2, GPx, and CAT, in obese males' livers. In addition, we assumed that the level of malondialdehyde (MDA) and protein carbonyl content (PCC) in obese males' livers would be reduced after E2 treatment as a result of E2 inhibitory effect on lipid peroxidation and protein oxidation, respectively. To test our hypothesis, we used the liver of a high-fat (HF) diet-fed male Wistar rats as an animal model of obesity, treated with E2 intraperitoneally (40 μg/kg). Preliminary results from this study support our hypothesis that E2 increases liver protein expression of AOS enzymes: SOD1, GPx, and CAT, in control and HF male rats compared with their respective controls. The protein level of SOD2 and CAT activity was increased in HF treated with E2 compared with non-treated HF rats. Moreover, as we expected, E2 administration significantly decreased the MDA level in both E2-treated groups compared to their controls, while the PCC level was significantly decreased in HF treated group compared with untreated HF rats. In conclusion, the preliminary results we obtained in this study indicate that E2 administration can effectively inhibit the OxS-related processes in the liver in HF diet-induced obesity by increasing AOS enzymes levels and CAT activity, and also by decreasing levels of MDA and PCC. A consequence of our hypothesis is that treatment with E2 may be an innovative way to improve obesity-related liver disease prevention and healing. © 2023 Elsevier Ltd",
journal = "Medical Hypotheses",
title = "Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?",
volume = "174",
pages = "111049",
doi = "10.1016/j.mehy.2023.111049"
}

Panić, A., Sudar-Milovanović, E., Stanimirović, J., Obradović, M. M., Zafirović, S., Soskić, S. S.,& Isenović, E. R.. (2023). Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?. in Medical Hypotheses, 174, 111049.
https://doi.org/10.1016/j.mehy.2023.111049

Panić A, Sudar-Milovanović E, Stanimirović J, Obradović MM, Zafirović S, Soskić SS, Isenović ER. Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?. in Medical Hypotheses. 2023;174:111049.
doi:10.1016/j.mehy.2023.111049 .

Panić, Anastasija, Sudar-Milovanović, Emina, Stanimirović, Julijana, Obradović, Milan M., Zafirović, Sonja, Soskić, Sanja S., Isenović, Esma R., "Does oestradiol treatment alleviate obesity-induced oxidative stress in the male liver?" in Medical Hypotheses, 174 (2023):111049,
https://doi.org/10.1016/j.mehy.2023.111049 . .

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Gluvić, Zoran
AU  - Banjac, Katarina
AU  - Rizzo, Manfredi
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10756
AB  - Cardiometabolic diseases (CMD) are a direct consequence of modern living and contribute to the development of multisystem diseases such as cardiovascular diseases and diabetes mellitus (DM). CMD has reached epidemic proportions worldwide. A sodium pump (Na + /K + -ATPase) is found in most eukaryotic cells’ membrane and controls many essential cellular functions directly or indirectly. This ion transporter and its isoforms are important in the pathogenesis of some pathological processes, including CMD. The structure and function of Na + /K + -ATPase, its expression and distribution in tissues, and its interactions with known ligands such as cardiotonic steroids and other suspected endogenous regulators are discussed in this review. In addition, we reviewed recent literature data related to the involvement of Na + /K + -ATPase activity dysfunction in CMD, focusing on the Na + /K + -ATPase as a potential therapeutic target in CMD.
T2  - Frontiers in Endocrinology
T1  - The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases
VL  - 14
DO  - 10.3389/fendo.2023.1150171
ER  - 

@article{
author = "Obradović, Milan M. and Sudar-Milovanović, Emina and Gluvić, Zoran and Banjac, Katarina and Rizzo, Manfredi and Isenović, Esma R.",
year = "2023",
abstract = "Cardiometabolic diseases (CMD) are a direct consequence of modern living and contribute to the development of multisystem diseases such as cardiovascular diseases and diabetes mellitus (DM). CMD has reached epidemic proportions worldwide. A sodium pump (Na + /K + -ATPase) is found in most eukaryotic cells’ membrane and controls many essential cellular functions directly or indirectly. This ion transporter and its isoforms are important in the pathogenesis of some pathological processes, including CMD. The structure and function of Na + /K + -ATPase, its expression and distribution in tissues, and its interactions with known ligands such as cardiotonic steroids and other suspected endogenous regulators are discussed in this review. In addition, we reviewed recent literature data related to the involvement of Na + /K + -ATPase activity dysfunction in CMD, focusing on the Na + /K + -ATPase as a potential therapeutic target in CMD.",
journal = "Frontiers in Endocrinology",
title = "The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases",
volume = "14",
doi = "10.3389/fendo.2023.1150171"
}

Obradović, M. M., Sudar-Milovanović, E., Gluvić, Z., Banjac, K., Rizzo, M.,& Isenović, E. R.. (2023). The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases. in Frontiers in Endocrinology, 14.
https://doi.org/10.3389/fendo.2023.1150171

Obradović MM, Sudar-Milovanović E, Gluvić Z, Banjac K, Rizzo M, Isenović ER. The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases. in Frontiers in Endocrinology. 2023;14.
doi:10.3389/fendo.2023.1150171 .

Obradović, Milan M., Sudar-Milovanović, Emina, Gluvić, Zoran, Banjac, Katarina, Rizzo, Manfredi, Isenović, Esma R., "The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases" in Frontiers in Endocrinology, 14 (2023),
https://doi.org/10.3389/fendo.2023.1150171 . .

TY  - JOUR
AU  - Mačvanin, Mirjana
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Stanimirović, Julijana
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10757
AB  - Metabolic diseases such as obesity, diabetes, dyslipidemia, and insulin resistance are characterized by glucose and lipid metabolism alterations and represent a global health problem. Many studies have established the crucial role of micro-ribonucleic acids (miRNAs) in controlling metabolic processes in various tissues. miRNAs are single-stranded, highly conserved non-coding RNAs containing 20-24 oligonucleotides that are expressed in a tissue-specific manner. miRNAs mainly interact through base pairing with 3' untranslated regions of target gene mRNAs to promote inhibition of their translation. miRNAs regulate the expression of as many as 30% of the human genes and have a role in crucial physiological processes such as human growth and development, cell proliferation, apoptosis, and metabolism. The number of miRNA molecules with a confirmed role in the pathogenesis of metabolic diseases is quickly expanding due to the availability of high-throughput methodologies for their identification. In this review, we present recent findings regarding the role of miRNAs as endocrine signaling molecules involved in the regulation of insulin production and fat metabolism. We discuss the potential of extracellular miRNAs present in biological fluids miRNAs as biomarkers for the prediction of diabetes and MetS. We also give an updated overview of therapeutic interventions based on antisense oligonucleotides and the CRISPR/Cas9 editing platform for manipulating levels of miRNAs involved in metabolic disorders. © 2023 Bentham Science Publishers.
T2  - Current Medicinal Chemistry
T1  - The Role of miRNAs in Metabolic Diseases
VL  - 30
IS  - 17
SP  - 1922
EP  - 1944
DO  - 10.2174/0929867329666220801161536
ER  - 

@article{
author = "Mačvanin, Mirjana and Obradović, Milan M. and Zafirović, Sonja and Stanimirović, Julijana and Isenović, Esma R.",
year = "2023",
abstract = "Metabolic diseases such as obesity, diabetes, dyslipidemia, and insulin resistance are characterized by glucose and lipid metabolism alterations and represent a global health problem. Many studies have established the crucial role of micro-ribonucleic acids (miRNAs) in controlling metabolic processes in various tissues. miRNAs are single-stranded, highly conserved non-coding RNAs containing 20-24 oligonucleotides that are expressed in a tissue-specific manner. miRNAs mainly interact through base pairing with 3' untranslated regions of target gene mRNAs to promote inhibition of their translation. miRNAs regulate the expression of as many as 30% of the human genes and have a role in crucial physiological processes such as human growth and development, cell proliferation, apoptosis, and metabolism. The number of miRNA molecules with a confirmed role in the pathogenesis of metabolic diseases is quickly expanding due to the availability of high-throughput methodologies for their identification. In this review, we present recent findings regarding the role of miRNAs as endocrine signaling molecules involved in the regulation of insulin production and fat metabolism. We discuss the potential of extracellular miRNAs present in biological fluids miRNAs as biomarkers for the prediction of diabetes and MetS. We also give an updated overview of therapeutic interventions based on antisense oligonucleotides and the CRISPR/Cas9 editing platform for manipulating levels of miRNAs involved in metabolic disorders. © 2023 Bentham Science Publishers.",
journal = "Current Medicinal Chemistry",
title = "The Role of miRNAs in Metabolic Diseases",
volume = "30",
number = "17",
pages = "1922-1944",
doi = "10.2174/0929867329666220801161536"
}

Mačvanin, M., Obradović, M. M., Zafirović, S., Stanimirović, J.,& Isenović, E. R.. (2023). The Role of miRNAs in Metabolic Diseases. in Current Medicinal Chemistry, 30(17), 1922-1944.
https://doi.org/10.2174/0929867329666220801161536

Mačvanin M, Obradović MM, Zafirović S, Stanimirović J, Isenović ER. The Role of miRNAs in Metabolic Diseases. in Current Medicinal Chemistry. 2023;30(17):1922-1944.
doi:10.2174/0929867329666220801161536 .

Mačvanin, Mirjana, Obradović, Milan M., Zafirović, Sonja, Stanimirović, Julijana, Isenović, Esma R., "The Role of miRNAs in Metabolic Diseases" in Current Medicinal Chemistry, 30, no. 17 (2023):1922-1944,
https://doi.org/10.2174/0929867329666220801161536 . .

TY  - JOUR
AU  - Mačvanin, Mirjana
AU  - Gluvić, Zoran
AU  - Radovanović, Jelena
AU  - Essack, Magbubah
AU  - Gao, Xin
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10774
AB  - Diabetes mellitus (DM) is on the rise, necessitating the development of novel therapeutic and preventive strategies to mitigate the disease’s debilitating effects. Diabetic cardiomyopathy (DCMP) is among the leading causes of morbidity and mortality in diabetic patients globally. DCMP manifests as cardiomyocyte hypertrophy, apoptosis, and myocardial interstitial fibrosis before progressing to heart failure. Evidence suggests that non-coding RNAs, such as long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), regulate diabetic cardiomyopathy-related processes such as insulin resistance, cardiomyocyte apoptosis and inflammation, emphasizing their heart-protective effects. This paper reviewed the literature data from animal and human studies on the non-trivial roles of miRNAs and lncRNAs in the context of DCMP in diabetes and demonstrated their future potential in DCMP treatment in diabetic patients.
T2  - Frontiers in Endocrinology
T1  - Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs
VL  - 14
DO  - 10.3389/fendo.2023.1124613
ER  - 

@article{
author = "Mačvanin, Mirjana and Gluvić, Zoran and Radovanović, Jelena and Essack, Magbubah and Gao, Xin and Isenović, Esma R.",
year = "2023",
abstract = "Diabetes mellitus (DM) is on the rise, necessitating the development of novel therapeutic and preventive strategies to mitigate the disease’s debilitating effects. Diabetic cardiomyopathy (DCMP) is among the leading causes of morbidity and mortality in diabetic patients globally. DCMP manifests as cardiomyocyte hypertrophy, apoptosis, and myocardial interstitial fibrosis before progressing to heart failure. Evidence suggests that non-coding RNAs, such as long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), regulate diabetic cardiomyopathy-related processes such as insulin resistance, cardiomyocyte apoptosis and inflammation, emphasizing their heart-protective effects. This paper reviewed the literature data from animal and human studies on the non-trivial roles of miRNAs and lncRNAs in the context of DCMP in diabetes and demonstrated their future potential in DCMP treatment in diabetic patients.",
journal = "Frontiers in Endocrinology",
title = "Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs",
volume = "14",
doi = "10.3389/fendo.2023.1124613"
}

Mačvanin, M., Gluvić, Z., Radovanović, J., Essack, M., Gao, X.,& Isenović, E. R.. (2023). Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs. in Frontiers in Endocrinology, 14.
https://doi.org/10.3389/fendo.2023.1124613

Mačvanin M, Gluvić Z, Radovanović J, Essack M, Gao X, Isenović ER. Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs. in Frontiers in Endocrinology. 2023;14.
doi:10.3389/fendo.2023.1124613 .

Mačvanin, Mirjana, Gluvić, Zoran, Radovanović, Jelena, Essack, Magbubah, Gao, Xin, Isenović, Esma R., "Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs" in Frontiers in Endocrinology, 14 (2023),
https://doi.org/10.3389/fendo.2023.1124613 . .

TY  - JOUR
AU  - Mačvanin, Mirjana
AU  - Gluvić, Zoran
AU  - Zarić, Božidarka
AU  - Essack, Magbubah
AU  - Gao, Xin
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11405
AB  - After the metabolic syndrome and its components, thyroid disorders represent the most common endocrine disorders, with increasing prevalence in the last two decades. Thyroid dysfunctions are distinguished by hyperthyroidism, hypothyroidism, or inflammation (thyroiditis) of the thyroid gland, in addition to the presence of thyroid nodules that can be benign or malignant. Thyroid cancer is typically detected via an ultrasound (US)-guided fine-needle aspiration biopsy (FNAB) and cytological examination of the specimen. This approach has significant limitations due to the small sample size and inability to characterize follicular lesions adequately. Due to the rapid advancement of high-throughput molecular biology techniques, it is now possible to identify new biomarkers for thyroid neoplasms that can supplement traditional imaging modalities in postoperative surveillance and aid in the preoperative cytology examination of indeterminate or follicular lesions. Here, we review current knowledge regarding biomarkers that have been reliable in detecting thyroid neoplasms, making them valuable tools for assessing the efficacy of surgical procedures or adjunctive treatment after surgery. We are particularly interested in providing an up-to-date and systematic review of emerging biomarkers, such as mRNA and non-coding RNAs, that can potentially detect thyroid neoplasms in clinical settings. We discuss evidence for miRNA, lncRNA and circRNA dysregulation in several thyroid neoplasms and assess their potential for use as diagnostic and prognostic biomarkers.
T2  - Frontiers in Endocrinology
T1  - New biomarkers: prospect for diagnosis and monitoring of thyroid disease
VL  - 14
SP  - 1218320
DO  - 10.3389/fendo.2023.1218320
ER  - 

@article{
author = "Mačvanin, Mirjana and Gluvić, Zoran and Zarić, Božidarka and Essack, Magbubah and Gao, Xin and Isenović, Esma R.",
year = "2023",
abstract = "After the metabolic syndrome and its components, thyroid disorders represent the most common endocrine disorders, with increasing prevalence in the last two decades. Thyroid dysfunctions are distinguished by hyperthyroidism, hypothyroidism, or inflammation (thyroiditis) of the thyroid gland, in addition to the presence of thyroid nodules that can be benign or malignant. Thyroid cancer is typically detected via an ultrasound (US)-guided fine-needle aspiration biopsy (FNAB) and cytological examination of the specimen. This approach has significant limitations due to the small sample size and inability to characterize follicular lesions adequately. Due to the rapid advancement of high-throughput molecular biology techniques, it is now possible to identify new biomarkers for thyroid neoplasms that can supplement traditional imaging modalities in postoperative surveillance and aid in the preoperative cytology examination of indeterminate or follicular lesions. Here, we review current knowledge regarding biomarkers that have been reliable in detecting thyroid neoplasms, making them valuable tools for assessing the efficacy of surgical procedures or adjunctive treatment after surgery. We are particularly interested in providing an up-to-date and systematic review of emerging biomarkers, such as mRNA and non-coding RNAs, that can potentially detect thyroid neoplasms in clinical settings. We discuss evidence for miRNA, lncRNA and circRNA dysregulation in several thyroid neoplasms and assess their potential for use as diagnostic and prognostic biomarkers.",
journal = "Frontiers in Endocrinology",
title = "New biomarkers: prospect for diagnosis and monitoring of thyroid disease",
volume = "14",
pages = "1218320",
doi = "10.3389/fendo.2023.1218320"
}

Mačvanin, M., Gluvić, Z., Zarić, B., Essack, M., Gao, X.,& Isenović, E. R.. (2023). New biomarkers: prospect for diagnosis and monitoring of thyroid disease. in Frontiers in Endocrinology, 14, 1218320.
https://doi.org/10.3389/fendo.2023.1218320

Mačvanin M, Gluvić Z, Zarić B, Essack M, Gao X, Isenović ER. New biomarkers: prospect for diagnosis and monitoring of thyroid disease. in Frontiers in Endocrinology. 2023;14:1218320.
doi:10.3389/fendo.2023.1218320 .

Mačvanin, Mirjana, Gluvić, Zoran, Zarić, Božidarka, Essack, Magbubah, Gao, Xin, Isenović, Esma R., "New biomarkers: prospect for diagnosis and monitoring of thyroid disease" in Frontiers in Endocrinology, 14 (2023):1218320,
https://doi.org/10.3389/fendo.2023.1218320 . .

TY  - JOUR
AU  - Alamri, Hasan S.
AU  - Mufti, Rana
AU  - Sabir, Deema Kamal
AU  - Abuderman, Abdulwahab A.
AU  - Dawood, Amal F.
AU  - ShamsEldeen, Asmaa M.
AU  - Haidara, Mohamed A.
AU  - Isenović, Esma R.
AU  - El-Bidawy, Mahmoud H.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11457
AB  - The first-generation antihistamine chlorpheniramine (CPA) is believed to have both anxiolytic and antidepressant properties. The current study sought to assess the mechanisms behind the antidepressant and anxiolytic effects of CPA therapy concerning oxidative stress, inflammation, and nuclear factor p45 for erythroid 2-Brain-derived neurotrophic factor (Nrf2-BDNF) signaling pathway in forced swimming-induced depressive-like behavior and anxiety. Eighteen male Wistar rats (180–200 gm) rats were separated into three groups (n = 6): a stressed group (acute stress) that underwent the forced swimming test (FST) and a stressed group that received pretreatment with CPA (10 mg/kg body weight) for 3 weeks (CPA + acute stress). Animals were subsequently put through the following behavioral tests after undergoing a forced swim test (FST) for 5 min: an immobility test, open field test, and elevated plus maze test. Serum cortisol levels were measured when the rats were euthanized at the end of the experiments. Brain neurotransmitters (cortisol, serotonin, and noradrenaline), oxidative stress (SOD and MDA), inflammatory (IL-6 and IL-1) biomarkers, and the Nrf2-BDNF signaling pathway in the hippocampus and cerebral cortex tissues was determined. CPA prevented stress-induced increases in cortisol levels (p < 0.0001), decreased brain neurotransmitters, and increased oxidative stress and inflammation. CPA also upregulated the Nrf2-BDNF signaling pathway. Thus, CPA mitigates depressive-like behavior and anxiety by inhibiting oxidative stress and inflammation and upregulating the Nrf2-BDNF signaling pathway in the brain tissues.
T2  - Current Issues in Molecular Biology
T1  - Forced Swimming-Induced Depressive-like Behavior and Anxiety Are Reduced by Chlorpheniramine via Suppression of Oxidative and Inflammatory Mediators and Activating the Nrf2-BDNF Signaling Pathway
VL  - 45
IS  - 8
SP  - 6449
EP  - 6465
DO  - 10.3390/cimb45080407
ER  - 

@article{
author = "Alamri, Hasan S. and Mufti, Rana and Sabir, Deema Kamal and Abuderman, Abdulwahab A. and Dawood, Amal F. and ShamsEldeen, Asmaa M. and Haidara, Mohamed A. and Isenović, Esma R. and El-Bidawy, Mahmoud H.",
year = "2023",
abstract = "The first-generation antihistamine chlorpheniramine (CPA) is believed to have both anxiolytic and antidepressant properties. The current study sought to assess the mechanisms behind the antidepressant and anxiolytic effects of CPA therapy concerning oxidative stress, inflammation, and nuclear factor p45 for erythroid 2-Brain-derived neurotrophic factor (Nrf2-BDNF) signaling pathway in forced swimming-induced depressive-like behavior and anxiety. Eighteen male Wistar rats (180–200 gm) rats were separated into three groups (n = 6): a stressed group (acute stress) that underwent the forced swimming test (FST) and a stressed group that received pretreatment with CPA (10 mg/kg body weight) for 3 weeks (CPA + acute stress). Animals were subsequently put through the following behavioral tests after undergoing a forced swim test (FST) for 5 min: an immobility test, open field test, and elevated plus maze test. Serum cortisol levels were measured when the rats were euthanized at the end of the experiments. Brain neurotransmitters (cortisol, serotonin, and noradrenaline), oxidative stress (SOD and MDA), inflammatory (IL-6 and IL-1) biomarkers, and the Nrf2-BDNF signaling pathway in the hippocampus and cerebral cortex tissues was determined. CPA prevented stress-induced increases in cortisol levels (p < 0.0001), decreased brain neurotransmitters, and increased oxidative stress and inflammation. CPA also upregulated the Nrf2-BDNF signaling pathway. Thus, CPA mitigates depressive-like behavior and anxiety by inhibiting oxidative stress and inflammation and upregulating the Nrf2-BDNF signaling pathway in the brain tissues.",
journal = "Current Issues in Molecular Biology",
title = "Forced Swimming-Induced Depressive-like Behavior and Anxiety Are Reduced by Chlorpheniramine via Suppression of Oxidative and Inflammatory Mediators and Activating the Nrf2-BDNF Signaling Pathway",
volume = "45",
number = "8",
pages = "6449-6465",
doi = "10.3390/cimb45080407"
}

Alamri, H. S., Mufti, R., Sabir, D. K., Abuderman, A. A., Dawood, A. F., ShamsEldeen, A. M., Haidara, M. A., Isenović, E. R.,& El-Bidawy, M. H.. (2023). Forced Swimming-Induced Depressive-like Behavior and Anxiety Are Reduced by Chlorpheniramine via Suppression of Oxidative and Inflammatory Mediators and Activating the Nrf2-BDNF Signaling Pathway. in Current Issues in Molecular Biology, 45(8), 6449-6465.
https://doi.org/10.3390/cimb45080407

Alamri HS, Mufti R, Sabir DK, Abuderman AA, Dawood AF, ShamsEldeen AM, Haidara MA, Isenović ER, El-Bidawy MH. Forced Swimming-Induced Depressive-like Behavior and Anxiety Are Reduced by Chlorpheniramine via Suppression of Oxidative and Inflammatory Mediators and Activating the Nrf2-BDNF Signaling Pathway. in Current Issues in Molecular Biology. 2023;45(8):6449-6465.
doi:10.3390/cimb45080407 .

Alamri, Hasan S., Mufti, Rana, Sabir, Deema Kamal, Abuderman, Abdulwahab A., Dawood, Amal F., ShamsEldeen, Asmaa M., Haidara, Mohamed A., Isenović, Esma R., El-Bidawy, Mahmoud H., "Forced Swimming-Induced Depressive-like Behavior and Anxiety Are Reduced by Chlorpheniramine via Suppression of Oxidative and Inflammatory Mediators and Activating the Nrf2-BDNF Signaling Pathway" in Current Issues in Molecular Biology, 45, no. 8 (2023):6449-6465,
https://doi.org/10.3390/cimb45080407 . .

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Samardžić, Vladimir
AU  - Mačvanin, Mirjana
AU  - Zafirović, Sonja
AU  - Gluvić, Zoran
AU  - Grubin, Jasmina
AU  - Gao, Xin
AU  - Essack, Magbubah
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11567
AB  - Thyroid nodules (TN) are localized morphological changes in the thyroid gland and can be benign or malignant.Objective: The present study investigates the relationships between biochemical markers in serum (s) and their homologs in washout (w) after fine-needle aspiration biopsy (FNAB) of the TN of interest and their correlation with cytology specimen findings.We investigated the relationships between serum biochemical markers nitric oxide (NO), thyroglobulin (TG), and calcitonin (CT), their homologs in washout after FNAB of the TN of interest, and cytology findings of biopsy samples classified according to the Bethesda system for thyroid cytopathology in this study, which included 86 subjects.Results: Washout TG (TGw) level positively correlates with the cytology finding of the biopsy. A higher level of TGw correlates with higher categories of the Bethesda classification and indicates a higher malignant potential. The levels of serum NO (NOs), serum TG (TGs), serum CT (CTs), and washout CT (CTw) do not correlate with the cytology finding of the biopsy, and the higher levels of washout NO (NOw) correspond to the more suspicious ultrasound findings.The findings of our study suggest that TGw and NOw could be used as potential predictors of malignancy in TN.
T2  - Frontiers in Endocrinology
T1  - Nitric oxide, thyroglobulin, and calcitonin: Unravelling the nature of thyroid nodules
VL  - 14
SP  - 1241223
DO  - 10.3389/fendo.2023.1241223
ER  - 

@article{
author = "Obradović, Milan M. and Samardžić, Vladimir and Mačvanin, Mirjana and Zafirović, Sonja and Gluvić, Zoran and Grubin, Jasmina and Gao, Xin and Essack, Magbubah and Isenović, Esma R.",
year = "2023",
abstract = "Thyroid nodules (TN) are localized morphological changes in the thyroid gland and can be benign or malignant.Objective: The present study investigates the relationships between biochemical markers in serum (s) and their homologs in washout (w) after fine-needle aspiration biopsy (FNAB) of the TN of interest and their correlation with cytology specimen findings.We investigated the relationships between serum biochemical markers nitric oxide (NO), thyroglobulin (TG), and calcitonin (CT), their homologs in washout after FNAB of the TN of interest, and cytology findings of biopsy samples classified according to the Bethesda system for thyroid cytopathology in this study, which included 86 subjects.Results: Washout TG (TGw) level positively correlates with the cytology finding of the biopsy. A higher level of TGw correlates with higher categories of the Bethesda classification and indicates a higher malignant potential. The levels of serum NO (NOs), serum TG (TGs), serum CT (CTs), and washout CT (CTw) do not correlate with the cytology finding of the biopsy, and the higher levels of washout NO (NOw) correspond to the more suspicious ultrasound findings.The findings of our study suggest that TGw and NOw could be used as potential predictors of malignancy in TN.",
journal = "Frontiers in Endocrinology",
title = "Nitric oxide, thyroglobulin, and calcitonin: Unravelling the nature of thyroid nodules",
volume = "14",
pages = "1241223",
doi = "10.3389/fendo.2023.1241223"
}

Obradović, M. M., Samardžić, V., Mačvanin, M., Zafirović, S., Gluvić, Z., Grubin, J., Gao, X., Essack, M.,& Isenović, E. R.. (2023). Nitric oxide, thyroglobulin, and calcitonin: Unravelling the nature of thyroid nodules. in Frontiers in Endocrinology, 14, 1241223.
https://doi.org/10.3389/fendo.2023.1241223

Obradović MM, Samardžić V, Mačvanin M, Zafirović S, Gluvić Z, Grubin J, Gao X, Essack M, Isenović ER. Nitric oxide, thyroglobulin, and calcitonin: Unravelling the nature of thyroid nodules. in Frontiers in Endocrinology. 2023;14:1241223.
doi:10.3389/fendo.2023.1241223 .

Obradović, Milan M., Samardžić, Vladimir, Mačvanin, Mirjana, Zafirović, Sonja, Gluvić, Zoran, Grubin, Jasmina, Gao, Xin, Essack, Magbubah, Isenović, Esma R., "Nitric oxide, thyroglobulin, and calcitonin: Unravelling the nature of thyroid nodules" in Frontiers in Endocrinology, 14 (2023):1241223,
https://doi.org/10.3389/fendo.2023.1241223 . .

TY  - JOUR
AU  - Ilinčić, Branislava
AU  - Tomić Naglić, Dragana
AU  - Čabarkapa, Velibor
AU  - Bajkin, Ivana
AU  - Plećaš Đurić, Aleksandra
AU  - Kolarski, Ivor
AU  - Bojović, Marko
AU  - Urošević, Ivana
AU  - Stokić, E.
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11569
AB  - Objective: Hypovitaminosis D may be associated with an increased susceptibility to infection, more severe COVID-19 forms, and a higher risk of death. The objective of this study was to investigate any possible connections between vitamin D status [as measured by serum 25-hydroxyvitamin D (25(OH)D) levels] and COVID-19 severity.  Patients and methods: In 2021, a cross-sectional study of consecutive adult COVID-19 patients was conducted. Anthropometric data, comorbidities, hospital setting, length of stay, respiratory support, outcome data, and vitamin D status were all evaluated.  Results: The length of hospitalization among participants (n = 74; mean age 57.64 ± 17.83 years, 55.4% male) was 18.58 ± 10 days, the majority of the hospital setting was a medical ward (67.6%), and the respiratory support in the form of mechanical ventilation was represented by 12.2%. Hypertension (54.1%), obesity (64.9%), and overweight (64.9%) were the most common cardiometabolic risk factors. In the study group, 44.6% of participants had severe vitamin D deficiency (< 30 nmol/l), while 8.1% had vitamin D insufficiency (50 - 74.9 nmol/l). Furthermore, patients with severe COVID-19 (semi-intensive care unit, intensive care unit) had significantly lower serum 25(OH)D levels (32.9 vs. 20.5 nmol/l; p = 0.007). Participants with severe vitamin D deficiency were older and had more prevalent hypertension, requiring mechanical ventilation; 24.2% experienced a fatal outcome.  Conclusions: Severe vitamin D deficiency may contribute significantly to the influence of other cardiometabolic risk factors in COVID-19.
T2  - European review for medical and pharmacological sciences
T1  - Association between vitamin D hypovitaminosis and severe forms of COVID-19
VL  - 27
IS  - 11
SP  - 5318
EP  - 5326
DO  - 10.26355/eurrev_202306_32651
ER  - 

@article{
author = "Ilinčić, Branislava and Tomić Naglić, Dragana and Čabarkapa, Velibor and Bajkin, Ivana and Plećaš Đurić, Aleksandra and Kolarski, Ivor and Bojović, Marko and Urošević, Ivana and Stokić, E. and Isenović, Esma R.",
year = "2023",
abstract = "Objective: Hypovitaminosis D may be associated with an increased susceptibility to infection, more severe COVID-19 forms, and a higher risk of death. The objective of this study was to investigate any possible connections between vitamin D status [as measured by serum 25-hydroxyvitamin D (25(OH)D) levels] and COVID-19 severity.  Patients and methods: In 2021, a cross-sectional study of consecutive adult COVID-19 patients was conducted. Anthropometric data, comorbidities, hospital setting, length of stay, respiratory support, outcome data, and vitamin D status were all evaluated.  Results: The length of hospitalization among participants (n = 74; mean age 57.64 ± 17.83 years, 55.4% male) was 18.58 ± 10 days, the majority of the hospital setting was a medical ward (67.6%), and the respiratory support in the form of mechanical ventilation was represented by 12.2%. Hypertension (54.1%), obesity (64.9%), and overweight (64.9%) were the most common cardiometabolic risk factors. In the study group, 44.6% of participants had severe vitamin D deficiency (< 30 nmol/l), while 8.1% had vitamin D insufficiency (50 - 74.9 nmol/l). Furthermore, patients with severe COVID-19 (semi-intensive care unit, intensive care unit) had significantly lower serum 25(OH)D levels (32.9 vs. 20.5 nmol/l; p = 0.007). Participants with severe vitamin D deficiency were older and had more prevalent hypertension, requiring mechanical ventilation; 24.2% experienced a fatal outcome.  Conclusions: Severe vitamin D deficiency may contribute significantly to the influence of other cardiometabolic risk factors in COVID-19.",
journal = "European review for medical and pharmacological sciences",
title = "Association between vitamin D hypovitaminosis and severe forms of COVID-19",
volume = "27",
number = "11",
pages = "5318-5326",
doi = "10.26355/eurrev_202306_32651"
}

Ilinčić, B., Tomić Naglić, D., Čabarkapa, V., Bajkin, I., Plećaš Đurić, A., Kolarski, I., Bojović, M., Urošević, I., Stokić, E.,& Isenović, E. R.. (2023). Association between vitamin D hypovitaminosis and severe forms of COVID-19. in European review for medical and pharmacological sciences, 27(11), 5318-5326.
https://doi.org/10.26355/eurrev_202306_32651

Ilinčić B, Tomić Naglić D, Čabarkapa V, Bajkin I, Plećaš Đurić A, Kolarski I, Bojović M, Urošević I, Stokić E, Isenović ER. Association between vitamin D hypovitaminosis and severe forms of COVID-19. in European review for medical and pharmacological sciences. 2023;27(11):5318-5326.
doi:10.26355/eurrev_202306_32651 .

Ilinčić, Branislava, Tomić Naglić, Dragana, Čabarkapa, Velibor, Bajkin, Ivana, Plećaš Đurić, Aleksandra, Kolarski, Ivor, Bojović, Marko, Urošević, Ivana, Stokić, E., Isenović, Esma R., "Association between vitamin D hypovitaminosis and severe forms of COVID-19" in European review for medical and pharmacological sciences, 27, no. 11 (2023):5318-5326,
https://doi.org/10.26355/eurrev_202306_32651 . .

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Gluvić, Zoran
AU  - Radovanović, Jelena
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11639
AB  - The current literature findings on autophagy’s beneficial and detrimental roles in diabetes mellitus (DM) and diabetes-related comorbidities were reviewed. The effects of oral hypoglycaemic medicines and autophagy in DM. Autophagy plays an important function in cellular homeostasis by promoting cell survival or initiating cell death in physiological settings was also assessed. Although autophagy protects insulin-target tissues, organelle failure caused by autophagy malfunction influences DM and other metabolic diseases. Endoplasmic reticulum and oxidative stress enhance autophagy levels, making it easier to regulate stress-induced intracellular changes. Evidence suggests that autophagy-caused cell death can occur when autophagy is overstimulated and constitutively activated, which might prevent or develop DM. Even though the precise role of autophagy in DM complications is uncertain, deregulation of the autophagic machinery is strongly linked to beta cell destruction and the aetiology of DM. Thus, improving autophagy dysfunction is a possible therapeutic objective in treating DM and other metabolic disorders.
T2  - Exploration of Medicine
T1  - Autophagy and diabetes
SP  - 576
EP  - 588
DO  - 10.37349/emed.2023.00162
ER  - 

@article{
author = "Obradović, Milan M. and Zafirović, Sonja and Gluvić, Zoran and Radovanović, Jelena and Isenović, Esma R.",
year = "2023",
abstract = "The current literature findings on autophagy’s beneficial and detrimental roles in diabetes mellitus (DM) and diabetes-related comorbidities were reviewed. The effects of oral hypoglycaemic medicines and autophagy in DM. Autophagy plays an important function in cellular homeostasis by promoting cell survival or initiating cell death in physiological settings was also assessed. Although autophagy protects insulin-target tissues, organelle failure caused by autophagy malfunction influences DM and other metabolic diseases. Endoplasmic reticulum and oxidative stress enhance autophagy levels, making it easier to regulate stress-induced intracellular changes. Evidence suggests that autophagy-caused cell death can occur when autophagy is overstimulated and constitutively activated, which might prevent or develop DM. Even though the precise role of autophagy in DM complications is uncertain, deregulation of the autophagic machinery is strongly linked to beta cell destruction and the aetiology of DM. Thus, improving autophagy dysfunction is a possible therapeutic objective in treating DM and other metabolic disorders.",
journal = "Exploration of Medicine",
title = "Autophagy and diabetes",
pages = "576-588",
doi = "10.37349/emed.2023.00162"
}

Obradović, M. M., Zafirović, S., Gluvić, Z., Radovanović, J.,& Isenović, E. R.. (2023). Autophagy and diabetes. in Exploration of Medicine, 576-588.
https://doi.org/10.37349/emed.2023.00162

Obradović MM, Zafirović S, Gluvić Z, Radovanović J, Isenović ER. Autophagy and diabetes. in Exploration of Medicine. 2023;:576-588.
doi:10.37349/emed.2023.00162 .

Obradović, Milan M., Zafirović, Sonja, Gluvić, Zoran, Radovanović, Jelena, Isenović, Esma R., "Autophagy and diabetes" in Exploration of Medicine (2023):576-588,
https://doi.org/10.37349/emed.2023.00162 . .

TY  - JOUR
AU  - Tomić, Aleksandra
AU  - Zafirović, Sonja
AU  - Gluvić, Zoran
AU  - Samardžić, Vladimir
AU  - Mačvanin, Mirjana
AU  - Radunović, Maja
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11875
AB  - Background:Subacute thyroiditis (SAT) is an organ-specific disease that various drugs, including COVID-19vaccines, can trigger. COVID-19 infection has been associated with thyroid gland damage and disease SARS-CoV-2direct action, euthyroid sick syndrome, and immune-mediated mechanisms are all potential mechanisms of thyroiddamage. It denotes thyroid gland inflammation, most commonly of viral origin, and belongs to the transitory, self-limiting thyroid gland diseases group, causing complications in approximately 15% of patients in the formof permanent hypothyroidism. Some authors say SAT is the most common thyroid disease associated withCOVID-19.Purpose:The occurrence of SAT many weeks after administering the second COVID-19 vaccine is rare and has limiteddocumentation in academic literature. This study aims to present the occurrence of SAT after administering the COVID-19vaccine. We present the case of a 37-year-old man who developed SAT 23 days after receiving the second dose of PfizerBioNTech’s COVID-19 mRNA vaccine.Research design and study sample:Due to neck pain and an elevated body temperature (up to 38.2°C), a 37-year-old male subject presented for examination 23 days after receiving the second Pfizer BioNTech mRNA vaccineagainst SARS-CoV-2 viral infection. The patient deniedever having an autoimmune disease or any other disease.Painful neck palpation and afirm, slightly enlarged thyroid gland with no surrounding lymphadenopathy wereidentified during the exam. The heart rate was 104 beatsper minute. All of the remaining physicalfindings werenormal.Data collection and/or Analysis:Data collected during the disease are integral to the medical record.Results:Hematology and biochemistry analyses at the initial and follow-up visits revealed minor leukocytosis, normocyticanaemia, and thrombocytosis, followed by a mild increase in lactate dehydrogenase and decreased iron levels. The patient’sthyroid function and morphology had recovered entirely from post-vaccine SAT.Conclusions: Results from this study emphasise the need for healthcare professionals to promptly report any case of SATrelated to COVID-19 vaccination. Further investigation is warranted to understand the immunopathogenesis of COVID-19-associated thyroiditis and the impact of COVID-19 immunization on this condition.
T2  - Antiviral Therapy
T1  - Subacute thyroiditis following COVID-19 vaccination: Case presentation
VL  - 28
IS  - 5
DO  - 10.1177/13596535231208831
ER  - 

@article{
author = "Tomić, Aleksandra and Zafirović, Sonja and Gluvić, Zoran and Samardžić, Vladimir and Mačvanin, Mirjana and Radunović, Maja and Isenović, Esma R.",
year = "2023",
abstract = "Background:Subacute thyroiditis (SAT) is an organ-specific disease that various drugs, including COVID-19vaccines, can trigger. COVID-19 infection has been associated with thyroid gland damage and disease SARS-CoV-2direct action, euthyroid sick syndrome, and immune-mediated mechanisms are all potential mechanisms of thyroiddamage. It denotes thyroid gland inflammation, most commonly of viral origin, and belongs to the transitory, self-limiting thyroid gland diseases group, causing complications in approximately 15% of patients in the formof permanent hypothyroidism. Some authors say SAT is the most common thyroid disease associated withCOVID-19.Purpose:The occurrence of SAT many weeks after administering the second COVID-19 vaccine is rare and has limiteddocumentation in academic literature. This study aims to present the occurrence of SAT after administering the COVID-19vaccine. We present the case of a 37-year-old man who developed SAT 23 days after receiving the second dose of PfizerBioNTech’s COVID-19 mRNA vaccine.Research design and study sample:Due to neck pain and an elevated body temperature (up to 38.2°C), a 37-year-old male subject presented for examination 23 days after receiving the second Pfizer BioNTech mRNA vaccineagainst SARS-CoV-2 viral infection. The patient deniedever having an autoimmune disease or any other disease.Painful neck palpation and afirm, slightly enlarged thyroid gland with no surrounding lymphadenopathy wereidentified during the exam. The heart rate was 104 beatsper minute. All of the remaining physicalfindings werenormal.Data collection and/or Analysis:Data collected during the disease are integral to the medical record.Results:Hematology and biochemistry analyses at the initial and follow-up visits revealed minor leukocytosis, normocyticanaemia, and thrombocytosis, followed by a mild increase in lactate dehydrogenase and decreased iron levels. The patient’sthyroid function and morphology had recovered entirely from post-vaccine SAT.Conclusions: Results from this study emphasise the need for healthcare professionals to promptly report any case of SATrelated to COVID-19 vaccination. Further investigation is warranted to understand the immunopathogenesis of COVID-19-associated thyroiditis and the impact of COVID-19 immunization on this condition.",
journal = "Antiviral Therapy",
title = "Subacute thyroiditis following COVID-19 vaccination: Case presentation",
volume = "28",
number = "5",
doi = "10.1177/13596535231208831"
}

Tomić, A., Zafirović, S., Gluvić, Z., Samardžić, V., Mačvanin, M., Radunović, M.,& Isenović, E. R.. (2023). Subacute thyroiditis following COVID-19 vaccination: Case presentation. in Antiviral Therapy, 28(5).
https://doi.org/10.1177/13596535231208831

Tomić A, Zafirović S, Gluvić Z, Samardžić V, Mačvanin M, Radunović M, Isenović ER. Subacute thyroiditis following COVID-19 vaccination: Case presentation. in Antiviral Therapy. 2023;28(5).
doi:10.1177/13596535231208831 .

Tomić, Aleksandra, Zafirović, Sonja, Gluvić, Zoran, Samardžić, Vladimir, Mačvanin, Mirjana, Radunović, Maja, Isenović, Esma R., "Subacute thyroiditis following COVID-19 vaccination: Case presentation" in Antiviral Therapy, 28, no. 5 (2023),
https://doi.org/10.1177/13596535231208831 . .

TY  - JOUR
AU  - Mačvanin, Mirjana
AU  - Gluvić, Zoran
AU  - Klisić, Aleksandra
AU  - Manojlović, Mia
AU  - Suri, Jasjit
AU  - Rizzo, Manfredi
AU  - Isenović, Esma
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12021
AB  - Cardiovascular disease (CDV) represents the major cause of death globally. Atherosclerosis, as the primary cause of CVD, is a chronic immune-inflammatory disorder with complex multifactorial pathophysiology encompassing oxidative stress, enhanced immune-inflammatory cascade, endothelial dysfunction, and thrombosis. An initiating event in atherosclerosis is the subendothelial accumulation of low-density lipoprotein (LDL), followed by the localization of macrophages to fatty deposits on blood vessel walls, forming lipid-laden macrophages (foam cells) that secrete compounds involved in plaque formation. Given the fact that foam cells are one of the key culprits that underlie the pathophysiology of atherosclerosis, special attention has been paid to the investigation of the efficient therapeutic approach to overcome the dysregulation of metabolism of cholesterol in macrophages, decrease the foam cell formation and/or to force its degradation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine proteinase that has emerged as a significant regulator of the lipid metabolism pathway. PCSK9 activation leads to the degradation of LDL receptors (LDLRs), increasing LDL cholesterol (LDL-C) levels in the circulation. PCSK9 pathway dysregulation has been identified as one of the mechanisms involved in atherosclerosis. In addition, microRNAs (miRNAs) are investigated as important epigenetic factors in the pathophysiology of atherosclerosis and dysregulation of lipid metabolism. This review article summarizes the recent findings connecting the role of PCSK9 in atherosclerosis and the involvement of various miRNAs in regulating the expression of PCSK9-related genes. We also discuss PCSK9 pathway-targeting therapeutic interventions based on PCSK9 inhibition, miRNA levels manipulation by therapeutic agents, and the most recent advances in PSCK9 gene editing using CRISPR/Cas9 platform, meganuclease, and base editors.
T2  - Current Medicinal Chemistry
T1  - The Link between miRNAs and PCKS9 in Atherosclerosis
VL  - 31
DO  - 10.2174/0109298673262124231102042914
ER  - 

@article{
author = "Mačvanin, Mirjana and Gluvić, Zoran and Klisić, Aleksandra and Manojlović, Mia and Suri, Jasjit and Rizzo, Manfredi and Isenović, Esma",
year = "2023",
abstract = "Cardiovascular disease (CDV) represents the major cause of death globally. Atherosclerosis, as the primary cause of CVD, is a chronic immune-inflammatory disorder with complex multifactorial pathophysiology encompassing oxidative stress, enhanced immune-inflammatory cascade, endothelial dysfunction, and thrombosis. An initiating event in atherosclerosis is the subendothelial accumulation of low-density lipoprotein (LDL), followed by the localization of macrophages to fatty deposits on blood vessel walls, forming lipid-laden macrophages (foam cells) that secrete compounds involved in plaque formation. Given the fact that foam cells are one of the key culprits that underlie the pathophysiology of atherosclerosis, special attention has been paid to the investigation of the efficient therapeutic approach to overcome the dysregulation of metabolism of cholesterol in macrophages, decrease the foam cell formation and/or to force its degradation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine proteinase that has emerged as a significant regulator of the lipid metabolism pathway. PCSK9 activation leads to the degradation of LDL receptors (LDLRs), increasing LDL cholesterol (LDL-C) levels in the circulation. PCSK9 pathway dysregulation has been identified as one of the mechanisms involved in atherosclerosis. In addition, microRNAs (miRNAs) are investigated as important epigenetic factors in the pathophysiology of atherosclerosis and dysregulation of lipid metabolism. This review article summarizes the recent findings connecting the role of PCSK9 in atherosclerosis and the involvement of various miRNAs in regulating the expression of PCSK9-related genes. We also discuss PCSK9 pathway-targeting therapeutic interventions based on PCSK9 inhibition, miRNA levels manipulation by therapeutic agents, and the most recent advances in PSCK9 gene editing using CRISPR/Cas9 platform, meganuclease, and base editors.",
journal = "Current Medicinal Chemistry",
title = "The Link between miRNAs and PCKS9 in Atherosclerosis",
volume = "31",
doi = "10.2174/0109298673262124231102042914"
}

Mačvanin, M., Gluvić, Z., Klisić, A., Manojlović, M., Suri, J., Rizzo, M.,& Isenović, E.. (2023). The Link between miRNAs and PCKS9 in Atherosclerosis. in Current Medicinal Chemistry, 31.
https://doi.org/10.2174/0109298673262124231102042914

Mačvanin M, Gluvić Z, Klisić A, Manojlović M, Suri J, Rizzo M, Isenović E. The Link between miRNAs and PCKS9 in Atherosclerosis. in Current Medicinal Chemistry. 2023;31.
doi:10.2174/0109298673262124231102042914 .

Mačvanin, Mirjana, Gluvić, Zoran, Klisić, Aleksandra, Manojlović, Mia, Suri, Jasjit, Rizzo, Manfredi, Isenović, Esma, "The Link between miRNAs and PCKS9 in Atherosclerosis" in Current Medicinal Chemistry, 31 (2023),
https://doi.org/10.2174/0109298673262124231102042914 . .

TY  - JOUR
AU  - Saba, Luca
AU  - Maindarkar, Mahesh
AU  - Khanna, Narendra N.
AU  - Johri, Amer M.
AU  - Mantella, Laura
AU  - Laird, John R.
AU  - Paraskevas, Kosmas I.
AU  - Ruzsa, Zoltan
AU  - Kalra, Manudeep K.
AU  - Fernandes, Jose Fernandes E.
AU  - Chaturvedi, Seemant
AU  - Nicolaides, Andrew
AU  - Rathore, Vijay
AU  - Singh, Narpinder
AU  - Fouda, Mostafa M.
AU  - Isenović, Esma R.
AU  - Al-Maini, Mustafa
AU  - Viswanathan, Vijay
AU  - Suri, Jasjit S.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12023
AB  - Background: Cardiovascular disease (CVD) is challenging to diagnose and treat since symptoms appear late during the progression of atherosclerosis. Conventional risk factors alone are not always sufficient to properly categorize at-risk patients, and clinical risk scores are inadequate in predicting cardiac events. Integrating genomic-based biomarkers (GBBM) found in plasma/serum samples with novel non-invasive radiomics-based biomarkers (RBBM) such as plaque area, plaque burden, and maximum plaque height can improve composite CVD risk prediction in the pharmaceutical paradigm. These biomarkers consider several pathways involved in the pathophysiology of atherosclerosis disease leading to CVD. Objective: This review proposes two hypotheses: (i) The composite biomarkers are strongly correlated and can be used to detect the severity of CVD/Stroke precisely, and (ii) an explainable artificial intelligence (XAI)-based composite risk CVD/Stroke model with survival analysis using deep learning (DL) can predict in preventive, precision, and personalized (aiP 3 ) framework benefiting the pharmaceutical paradigm. Method: The PRISMA search technique resulted in 214 studies assessing composite biomarkers using radiogenomics for CVD/Stroke. The study presents a XAI model using AtheroEdge TM  4.0 to determine the risk of CVD/Stroke in the pharmaceutical framework using the radiogenomics biomarkers. Conclusions: Our observations suggest that the composite CVD risk biomarkers using radiogenomics provide a new dimension to CVD/Stroke risk assessment. The proposed review suggests a unique, unbiased, and XAI model based on AtheroEdge TM  4.0 that can predict the composite risk of CVD/Stroke using radiogenomics in the pharmaceutical paradigm.
T2  - Frontiers in Bioscience-Landmark
T1  - A Pharmaceutical Paradigm for Cardiovascular Composite Risk Assessment Using Novel Radiogenomics Risk Predictors in Precision Explainable Artificial Intelligence Framework: Clinical Trial Tool
VL  - 28
IS  - 10
SP  - 248
DO  - 10.31083/j.fbl2810248
ER  - 

@article{
author = "Saba, Luca and Maindarkar, Mahesh and Khanna, Narendra N. and Johri, Amer M. and Mantella, Laura and Laird, John R. and Paraskevas, Kosmas I. and Ruzsa, Zoltan and Kalra, Manudeep K. and Fernandes, Jose Fernandes E. and Chaturvedi, Seemant and Nicolaides, Andrew and Rathore, Vijay and Singh, Narpinder and Fouda, Mostafa M. and Isenović, Esma R. and Al-Maini, Mustafa and Viswanathan, Vijay and Suri, Jasjit S.",
year = "2023",
abstract = "Background: Cardiovascular disease (CVD) is challenging to diagnose and treat since symptoms appear late during the progression of atherosclerosis. Conventional risk factors alone are not always sufficient to properly categorize at-risk patients, and clinical risk scores are inadequate in predicting cardiac events. Integrating genomic-based biomarkers (GBBM) found in plasma/serum samples with novel non-invasive radiomics-based biomarkers (RBBM) such as plaque area, plaque burden, and maximum plaque height can improve composite CVD risk prediction in the pharmaceutical paradigm. These biomarkers consider several pathways involved in the pathophysiology of atherosclerosis disease leading to CVD. Objective: This review proposes two hypotheses: (i) The composite biomarkers are strongly correlated and can be used to detect the severity of CVD/Stroke precisely, and (ii) an explainable artificial intelligence (XAI)-based composite risk CVD/Stroke model with survival analysis using deep learning (DL) can predict in preventive, precision, and personalized (aiP 3 ) framework benefiting the pharmaceutical paradigm. Method: The PRISMA search technique resulted in 214 studies assessing composite biomarkers using radiogenomics for CVD/Stroke. The study presents a XAI model using AtheroEdge TM  4.0 to determine the risk of CVD/Stroke in the pharmaceutical framework using the radiogenomics biomarkers. Conclusions: Our observations suggest that the composite CVD risk biomarkers using radiogenomics provide a new dimension to CVD/Stroke risk assessment. The proposed review suggests a unique, unbiased, and XAI model based on AtheroEdge TM  4.0 that can predict the composite risk of CVD/Stroke using radiogenomics in the pharmaceutical paradigm.",
journal = "Frontiers in Bioscience-Landmark",
title = "A Pharmaceutical Paradigm for Cardiovascular Composite Risk Assessment Using Novel Radiogenomics Risk Predictors in Precision Explainable Artificial Intelligence Framework: Clinical Trial Tool",
volume = "28",
number = "10",
pages = "248",
doi = "10.31083/j.fbl2810248"
}

Saba, L., Maindarkar, M., Khanna, N. N., Johri, A. M., Mantella, L., Laird, J. R., Paraskevas, K. I., Ruzsa, Z., Kalra, M. K., Fernandes, J. F. E., Chaturvedi, S., Nicolaides, A., Rathore, V., Singh, N., Fouda, M. M., Isenović, E. R., Al-Maini, M., Viswanathan, V.,& Suri, J. S.. (2023). A Pharmaceutical Paradigm for Cardiovascular Composite Risk Assessment Using Novel Radiogenomics Risk Predictors in Precision Explainable Artificial Intelligence Framework: Clinical Trial Tool. in Frontiers in Bioscience-Landmark, 28(10), 248.
https://doi.org/10.31083/j.fbl2810248

Saba L, Maindarkar M, Khanna NN, Johri AM, Mantella L, Laird JR, Paraskevas KI, Ruzsa Z, Kalra MK, Fernandes JFE, Chaturvedi S, Nicolaides A, Rathore V, Singh N, Fouda MM, Isenović ER, Al-Maini M, Viswanathan V, Suri JS. A Pharmaceutical Paradigm for Cardiovascular Composite Risk Assessment Using Novel Radiogenomics Risk Predictors in Precision Explainable Artificial Intelligence Framework: Clinical Trial Tool. in Frontiers in Bioscience-Landmark. 2023;28(10):248.
doi:10.31083/j.fbl2810248 .

Saba, Luca, Maindarkar, Mahesh, Khanna, Narendra N., Johri, Amer M., Mantella, Laura, Laird, John R., Paraskevas, Kosmas I., Ruzsa, Zoltan, Kalra, Manudeep K., Fernandes, Jose Fernandes E., Chaturvedi, Seemant, Nicolaides, Andrew, Rathore, Vijay, Singh, Narpinder, Fouda, Mostafa M., Isenović, Esma R., Al-Maini, Mustafa, Viswanathan, Vijay, Suri, Jasjit S., "A Pharmaceutical Paradigm for Cardiovascular Composite Risk Assessment Using Novel Radiogenomics Risk Predictors in Precision Explainable Artificial Intelligence Framework: Clinical Trial Tool" in Frontiers in Bioscience-Landmark, 28, no. 10 (2023):248,
https://doi.org/10.31083/j.fbl2810248 . .

TY  - JOUR
AU  - Dugalić, Predrag
AU  - Đuranović, Srđan
AU  - Dugalić, Vladimir
AU  - Stanković, Marjan
AU  - Isenović, Esma
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12024
AB  - Introduction: Barrett’s esophagus (BE) represents the distal esophageal epithelium changes that carry a high risk of developing esophageal adenocarcinoma. One of the most challenging aspects of diagnosing BE by endoscopy is precisely discerning between normal epithelium and BE changes, which is essential for therapy success. The objectives of this study were to compare the success of radio-frequency ablation (RFA) therapy to conservative treatment with proton pump inhibitor (PPI) drugs between the clinical presentation and endoscopy findings of BE at 2, 6, 12, and 24 months after administered therapy. Material and methods: Seventy-five subjects were divided into two groups (RFA and PPI) based on the BE treatment regimen in this case-control study to compare the quality of treatments applied over a  24-month follow-up. Subjects who received RFA therapy were further divided into groups: those who received focal HALO 90 and those who received circumferential HALO 360, based primarily on EGDS findings or endoscopist experience. Results: The results show that using the RFA therapeutic modality in the treatment of BE is more effective (by 94.2% in the second month of follow-up, i.e., by 99% at the final visit after 24 months) than using PPI therapy alone. Re-RFA therapy was given to 15% of the subjects, mostly applied in the same therapeutic modality (HALO 90). Conclusions: Our findings show that RFA and re-RFA therapy have a  high efficacy and safety profile, with no registered worsening of histology findings, the occurrence of esophageal adenocarcinoma, or adverse effects of the therapy.
T2  - Archives of Medical Science
T1  - Treatment of Barrett's Esophagus with radiofrequency ablation
DO  - 10.5114/aoms/159314
ER  - 

@article{
author = "Dugalić, Predrag and Đuranović, Srđan and Dugalić, Vladimir and Stanković, Marjan and Isenović, Esma",
year = "2023",
abstract = "Introduction: Barrett’s esophagus (BE) represents the distal esophageal epithelium changes that carry a high risk of developing esophageal adenocarcinoma. One of the most challenging aspects of diagnosing BE by endoscopy is precisely discerning between normal epithelium and BE changes, which is essential for therapy success. The objectives of this study were to compare the success of radio-frequency ablation (RFA) therapy to conservative treatment with proton pump inhibitor (PPI) drugs between the clinical presentation and endoscopy findings of BE at 2, 6, 12, and 24 months after administered therapy. Material and methods: Seventy-five subjects were divided into two groups (RFA and PPI) based on the BE treatment regimen in this case-control study to compare the quality of treatments applied over a  24-month follow-up. Subjects who received RFA therapy were further divided into groups: those who received focal HALO 90 and those who received circumferential HALO 360, based primarily on EGDS findings or endoscopist experience. Results: The results show that using the RFA therapeutic modality in the treatment of BE is more effective (by 94.2% in the second month of follow-up, i.e., by 99% at the final visit after 24 months) than using PPI therapy alone. Re-RFA therapy was given to 15% of the subjects, mostly applied in the same therapeutic modality (HALO 90). Conclusions: Our findings show that RFA and re-RFA therapy have a  high efficacy and safety profile, with no registered worsening of histology findings, the occurrence of esophageal adenocarcinoma, or adverse effects of the therapy.",
journal = "Archives of Medical Science",
title = "Treatment of Barrett's Esophagus with radiofrequency ablation",
doi = "10.5114/aoms/159314"
}

Dugalić, P., Đuranović, S., Dugalić, V., Stanković, M.,& Isenović, E.. (2023). Treatment of Barrett's Esophagus with radiofrequency ablation. in Archives of Medical Science.
https://doi.org/10.5114/aoms/159314

Dugalić P, Đuranović S, Dugalić V, Stanković M, Isenović E. Treatment of Barrett's Esophagus with radiofrequency ablation. in Archives of Medical Science. 2023;.
doi:10.5114/aoms/159314 .

Dugalić, Predrag, Đuranović, Srđan, Dugalić, Vladimir, Stanković, Marjan, Isenović, Esma, "Treatment of Barrett's Esophagus with radiofrequency ablation" in Archives of Medical Science (2023),
https://doi.org/10.5114/aoms/159314 . .